Author: "University of Catania [Italy]" / Topic: business - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"University of Catania [Italy]"' showing total 67 results

Start Over Author "University of Catania [Italy]" Topic business

67 results on '"University of Catania [Italy]"'

1. Epidemiology of Primary Brain Tumors in the Province of Catania during the 2003-2016 Period

Author: Alessandra Nicoletti, Chaima Chebil, Margherita Ferrante, Farid Boumediene, Antonietta Torrisi, Pierre-Marie Preux, Calogero Edoardo Cicero, Mario Zappia, Antonella Ippolito, Salvatore Sciacca, Alessia Di Prima, Cristina Rascunà, Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Catania [Italy], IOM Ricerca Srl [Catania, Italy], Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, and Université de Limoges (UNILIM)
Subjects: Male, medicine.medical_specialty, Epidemiology, 030501 epidemiology, Meningioma, Central Nervous System Neoplasms, 03 medical and health sciences, Primary brain tumors, 0302 clinical medicine, Internal medicine, medicine, Meningeal Neoplasms, Humans, Registries, Survival rate, Survival analysis, business.industry, Brain Neoplasms, Incidence (epidemiology), Incidence, Cancer registry, medicine.disease, Province of Catania, Confidence interval, 3. Good health, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), 0305 other medical science, business, 030217 neurology & neurosurgery, International Classification of Diseases for Oncology
Abstract: Introduction: Primary brain tumors (PBTs) account for approximately 2% of all cancers and are associated with significant morbidity and mortality. However, only few epidemiological studies focus on PBTs in Italy. The aim of this study was to evaluate incidence, temporal trend, and survival rate of all PBTs in the province of Catania during the study period. Methods: All patients diagnosed with PBTs in the province of Catania during the 2003-2016 were identified through the local cancer registry. All cases were classified by histology according to 2007 WHO classification of central nervous system tumors, using the International Classification of Diseases for Oncology, 3rd edition codes. The incidence rate (IR) was calculated for all PBTs and by gender, histology, age-groups, and behavior. Trend analysis was performed using a piecewise log-linear model. Results: A total of 3,819 cases were identified with a female/male ratio of 1.45. The IR for all PBTs was 25.3/100,000 person-years (95% confidence interval 24.5–26.1). Most PBTs were nonmalignant (59.5%, IR = 15.0) with a female predominance. Conversely, malignant tumors (32.4%, IR = 8.2) were more common among men, with a female/male ratio of 0.9. The most frequently reported histology was meningioma (39.0%, IR = 9.8), followed by glioblastoma (11.6%, IR = 2.9). A peak of incidence was found in the 75–84 years age-group, with an IR of 77.6/100,000 person-years. Overall, no increase in incidence was observed along the study period. Conclusions: The IR of PBTs in the province of Catania is close to incidence reported worldwide. Further studies on risk factors are necessary.
Published: 2021

2. Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study

Author: Martine El-Etr, Jérôme De Seze, Patrick Hautecoeur, Françoise Durand-Dubief, Jean Pelletier, Etienne-Emile Baulieu, Francesco Patti, David-Axel Laplaud, L. Gignoux, Maria Trojano, Emmanuelle Le Page, Sandra Vukusic, Pierre Clavelou, Luca Durelli, Iuliana Ionescu, David Brassat, Eric Berger, Catherine Cornu, Laurent Remontet, Nadine Bossard, Giovanni Castelnovo, Marc Debouverie, François Cotton, Olivier Heinzlef, Romain Marignier, Thibault Moreau, Christine Lebrun-Frenay, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), Observatoire Français de la Sclérose En Plaques [Lyon] (OFSEP), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service Hospitalo-Universitaire de Pharmacologie et Toxicologie - Lyon (SHUPT Lyon), Service de Biostatistiques [Lyon], Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Neuroradiologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Università degli studi di Torino = University of Turin (UNITO), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), CHU Strasbourg, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pôle Neurosciences [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance Publique - Hôpitaux de Marseille (APHM), Unité de Recherche Clinique de la Côte d’Azur (URRIS UR2CA), Centre Hospitalier Universitaire de Nice (CHU Nice)-Université Côte d'Azur (UCA), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service de Neurologie [CHU Nimes] (Pôle NIRR), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département de neurologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHI Poissy-Saint-Germain, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), University of Catania [Italy], Petites Molécules de neuroprotection, neurorégénération et remyélinisation, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Association Européenne contre les Leucodystrophies, Myelin Project, Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, Programme Hospitalier de Recherche Clinique 2005, Ministère des Affaires Sociales et de la Santé, Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli studi di Torino (UNITO), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pôle neurosciences [Hôpital de Purpan - Toulouse], CHU Toulouse [Toulouse], Unité de Recherche Clinique de la Côte d’Azur [Nice] (URRIS UR2CA), Université Côte d'Azur (UCA), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Università degli studi di Bari Aldo Moro (UNIBA), and Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL)
Subjects: Nomegestrol acetate, medicine.medical_specialty, relapses, Norpregnadienes, [SDV]Life Sciences [q-bio], Relapse rate, progesterone, Gastroenterology, sex hormones, Multiple sclerosis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Recurrence, Internal medicine, estradiol, Medicine, Humans, Post partum, Transdermal, business.industry, Postpartum Period, post-partum, Megestrol, medicine.disease, 17 beta estradiol, 3. Good health, Neurology, chemistry, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, 030215 immunology
Abstract: Background: Sex steroids could explain the course of multiple sclerosis (MS) in pregnancy. Objective: To compare the annualized relapse rate (ARR) 12 weeks post-partum in women treated with nomegestrol acetate (NOMAc) and 17-beta-estradiol (E2) versus placebo. Methods: POPARTMUS is a randomized, proof-of-concept trial in women with MS, receiving oral NOMAc 10 mg/day and transdermal estradiol 75 µg/week, or placebo. Results: Recruitment was stopped prematurely due to slow inclusions ( n = 202). No treatment effect was observed on ARR after 12 weeks (sex steroids = 0.90 (0.58–1.39), placebo = 0.97 (0.63–1.50) ( p = 0.79)). Conclusion: POPARTMUS failed showing efficacy of a NOMAc–E2 combination in preventing post-partum relapses.
Published: 2021

3. Analysis and Design of Bessel Beam Launchers: Transverse Polarization

Author: Santi C. Pavone, Mauro Ettorre, Massimiliano Casaletti, Matteo Albani, University of Catania [Italy], Institut d'Électronique et des Technologies du numéRique (IETR), Université de Nantes (UN)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), Laboratoire Génie électrique et électronique de Paris (GeePs), CentraleSupélec-Sorbonne Université (SU)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Siena = University of Siena (UNISI), Université de Nantes (UN)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), and Nantes Université (NU)-Université de Rennes 1 (UR1)
Subjects: Diffraction, Physics, Radial line slot array (RLSA), Field (physics), business.industry, Aperture, Nondiffractive beams, Astrophysics::Instrumentation and Methods for Astrophysics, RLSA, Bessel beams, Polarization (waves), non-diffractive beams, symbols.namesake, Transverse plane, [SPI]Engineering Sciences [physics], Optics, circular polarization, Bessel beam, symbols, near-field focusing, Electrical and Electronic Engineering, business, Bessel function, Beam (structure)
Abstract: International audience; In this paper, we present a theoretical analysis, one design and fabrication of a limited-diffractive planar Bessel beam launcher, that exhibits a zeroth order Bessel profile in the transverse electric field component with respect to the z-propagation axis. The launcher is designed by synthesizing a finite zeroth order, first kind Hankel aperture distribution, polarized along a fixed polarization unit vector. The field radiated by such an aperture distribution is derived by following an approximate model based on geometric theory of diffraction, thus allowing to highlight the relevant wave constituents involved in transverse Bessel beam generation, also including the effect of aperture truncation on the radiated beam. Moreover, the theoretical analysis has been profitably applied to the design of a circularpolarized planar transverse Bessel beam launcher by means of a slotted radial waveguide. A prototype of right-handed circular polarized (RHCP) transverse Bessel beam launcher has been then fabricated at f = 30 GHz. The measured transverse electric field component shows a satisfactory agreement with full-wave numerical simulations. IEEE
Published: 2021

4. Toxoplasma gondii and multiple sclerosis: A systematic review and meta-analysis

Author: Alessandra Nicoletti, Pierre-Marie Preux, Francesca Elsa Allibrio, Loretta Giuliano, Calogero Edoardo Cicero, Jaime Luna, University of Catania [Italy], Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, and Université de Limoges (UNILIM)
Subjects: medicine.medical_specialty, Multiple Sclerosis, Protective factor, Toxoplasma gondii, Antibodies, Protozoan, hygiene hypothesis, 03 medical and health sciences, Global population, 0302 clinical medicine, Hygiene hypothesis, Risk Factors, Seroepidemiologic Studies, Internal medicine, parasitic diseases, Medicine, Humans, 030304 developmental biology, parasitic infections, 0303 health sciences, biology, business.industry, Multiple sclerosis, Odds ratio, biology.organism_classification, medicine.disease, Confidence interval, 3. Good health, meta-analysis, Neurology, Meta-analysis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), business, Toxoplasma, 030217 neurology & neurosurgery, Toxoplasmosis
Abstract: International audience; Background and purpose: According to the hygiene hypothesis, infections by agents such as parasites have a protective role against the risk of developing multiple sclerosis (MS). Among parasites, Toxoplasma gondii, an intracellular parasite, showed evidence of a protective effect. This study was undertaken to summarize the available evidence on the association between T. gondii infection and MS. Methods: A systematic review of all the available articles published up to November 2020 has been conducted independently by two investigators in the following databases: PubMed, Scopus, Lissa, and SciELO. The association between T. gondii infection and MS has been pooled with a random effects model. Results: From 562 articles, seven were included in the systematic review and meta-analysis for a global population of 752 MS cases and 1282 controls. T. gondii infection was associated with MS with a pooled odds ratio of 0.68 (95% confidence interval = 0.50-0.93). Conclusions: The available evidence supports the hypothesis that T. gondii infection represents a protective factor against the development of MS.
Published: 2021

5. Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach

Author: Alessandra Nicoletti, Joseph Jankovic, Loretta Giuliano, Calogero Edoardo Cicero, Mario Zappia, Clara Grazia Chisari, Roberta Terranova, Pierre-Marie Preux, Marco Davì, Antonina Luca, Claudio Terravecchia, Cristina Rascunà, Giovanni Mostile, IRCCS Associazione Oasi Maria SS, Institute for Research on Mental Retardation and Brain Aging, Troina (EN), Italy, University of Catania [Italy], University of Palermo, Italy, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges (UNILIM), and Baylor College of Medecine
Subjects: 0301 basic medicine, Retinal degeneration, Male, medicine.medical_specialty, Head tremor, Timed up and go test, Retina, 03 medical and health sciences, 0302 clinical medicine, Physical medicine and rehabilitation, 80 and over, Neurologic, Medicine, Humans, Cognitive Dysfunction, Gait Disorders, Cognitive decline, Neurodegeneration, Tomography, Gait Disorders, Neurologic, Aged, Aged, 80 and over, Essential tremor, Optical coherence tomography, business.industry, Neuropsychology, Cognition, Neurodegenerative Diseases, medicine.disease, Action tremor, Gait, 030104 developmental biology, Neurology, Optical Coherence, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery, Tomography, Optical Coherence
Abstract: Introduction Essential Tremor (ET) is increasingly recognized as a complex disorder with additional clinical signs other than tremor. It is still unknown whether a unique pathophysiologic or neurodegenerative process underlies progression and prognosis of the disease. The aim of the study was to identify ET phenotypes through a clinical-instrumental data-driven approach and to characterize possible patterns of neurodegeneration. Methods ET patients were categorized using spatio-temporal and kinematic variables related to mobility and dynamic stability processed by motion transducers. Differences between the identified groups in clinical-demographic variables, neuropsychological performances and retinal parameters by Optical Coherence Tomography (OCT) segmentation analysis were tested. Results Twenty-five ET patients were studied. Based on clustering of kinematic and spatio-temporal gait parameters, two independent groups were identified: cluster “A” (N = 15) and cluster “B” (N = 10). Compared to group A, group B had overall worse performance in mobility, especially on turning tasks. Identified clusters did not differ in terms of age, age at onset and disease duration. Patients in group B had more head tremor and more severe action tremor in the upper limbs as compared to group A, demonstrating also worse performances on cognitive assessments. Based on OCT analysis, group B presented a reduced thickness of the retinal inner layer as compared to group A, suggesting underlying neurodegenerative processes. Conclusions The presence of gait and mobility impairment, associated with midline tremor, cognitive decline and retinal degeneration suggests a subtype of ET associated with neurodegeneration.
Published: 2021

6. Mortality following Clostridioides difficile infection in Europe

Author: Czepiel, Jacek, Krutova, Marcela, Mizrahi, Assaf, Khanafer, Nagham, Enoch, David A., Patyi, Márta, Deptuła, Aleksander, Agodi, Antonella, Nuvials, Xavier, Pituch, Hanna, Wójcik-Bugajska, Małgorzata, Filipczak-Bryniarska, Iwona, Brzozowski, Bartosz, Krzanowski, Marcin, Konturek, Katarzyna, Fedewicz, Marcin, Michalak, Mateusz, Monpierre, Lorra, Vanhems, Philippe, Gouliouris, Theodore, Jurczyszyn, Artur, Goldman-Mazur, Sarah, Wultańska, Dorota, Kuijper, Ed J., Skupień, Jan, Biesiada, Grażyna, Garlicki, Aleksander, Universitat Autònoma de Barcelona, Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Charles University [Prague] (CU), ESCMID Study Group for Clostridioides Difficile (ESGCD), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), AgroParisTech-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Groupe Hospitalier Paris Saint-Joseph (hpsj), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Addenbrooke's Hospital, Cambridge University NHS Trust, Bács-Kiskun County Teaching Hospital, Nicolaus Copernicus University [Toruń], University of Catania [Italy], Vall d'Hebron University Hospital [Barcelona], Medical University of Warsaw - Poland, University Hospital of Cracow/Szpital Uniwersytecki w Krakowie [Poland] (SUK), Józef Babinski Hospital, Ludwik Rydygier Hospital, Leiden University Medical Center (LUMC), Universiteit Leiden, Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Institut Català de la Salut, [Czepiel J] Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Krakow, Poland. [Krutova M] Department of Medical Microbiology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic. ESCMID Study Group for Clostridioides Difficile (ESGCD), Basel, Switzerland. [Mizrahi A] ESCMID Study Group for Clostridioides Difficile (ESGCD), Basel, Switzerland. Service de Microbiologie Clinique, Groupe Hospitalier Paris Saint-Joseph, Paris, France. Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France. [Khanafer N] ESCMID Study Group for Clostridioides Difficile (ESGCD), Basel, Switzerland. Unité d’Hygiène, Epidémiologie et Prévention, Groupement Hospitalier Centre, Hospices Civils de Lyon, Lyon, France. Centre International de Recherche en Infectiologie (CIRI), Public Health, Epidemiology and Evolutionary Ecology of Infectious Diseases (PHE3ID), Université de Lyon, Lyon, France. [Enoch DA] Clinical Microbiology & Public Health Laboratory, Public Health England, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK. [Patyi M] Hygienic Department, Bács-Kiskun County Teaching Hospital, Bács-Kiskun, Hungary. [Nuvials X] Servei de Medicina Intensiva, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de recerca SODIR, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Casal, Bérengère
Subjects: 0301 basic medicine, genetic structures, Clostridioides difficile infection, [SDV]Life Sciences [q-bio], Antibiotics, técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de casos y controles [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Logistic regression, Biochemistry, chemistry.chemical_compound, 0302 clinical medicine, Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Clostridium Infections [DISEASES], risk factors, Pharmacology (medical), 030212 general & internal medicine, Co-morbidities, General Pharmacology, Toxicology and Pharmaceutics, Outcome, Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Case-Control Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Clostridi - Europa, [SDV] Life Sciences [q-bio], Infectious Diseases, Absolute neutrophil count, outcome, localizaciones geográficas::Europa (continente) [DENOMINACIONES GEOGRÁFICAS], Microbiology (medical), medicine.medical_specialty, infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Clostridium [ENFERMEDADES], medicine.drug_class, 030106 microbiology, Malignancy, Geographic Locations::Europe [GEOGRAPHICALS], Microbiology, Cachexia, 03 medical and health sciences, Internal medicine, Other subheadings::Other subheadings::Other subheadings::/mortality [Other subheadings], medicine, Mortality, Creatinine, Clostridioides Clostridioides difficile infection, Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad [Otros calificadores], business.industry, lcsh:RM1-950, Case-control study, medicine.disease, mortality, co-morbidities, lcsh:Therapeutics. Pharmacology, chemistry, Risk factors, co–morbidities, Malalties bacterianes - Estudi de casos, business, Clostridioides, malignancy
Abstract: We aimed to describe the clinical presentation, treatment, outcome and report on factors associated with mortality over a 90-day period in Clostridioides difficile infection (CDI). Descriptive, univariate, and multivariate regression analyses were performed on data collected in a retrospective case-control study conducted in nine hospitals from seven European countries. A total of 624 patients were included, of which 415 were deceased (cases) and 209 were still alive 90 days after a CDI diagnosis (controls). The most common antibiotics used previously in both groups were β-lactams, previous exposure to fluoroquinolones was significantly (p = 0.0004) greater in deceased patients. Multivariate logistic regression showed that the factors independently related with death during CDI were older age, inadequate CDI therapy, cachexia, malignancy, Charlson Index, long-term care, elevated white blood cell count (WBC), C-reactive protein (CRP), bacteraemia, complications, and cognitive impairment. In addition, older age, higher levels of WBC, neutrophil, CRP or creatinine, the presence of malignancy, cognitive impairment, and complications were strongly correlated with shortening the time from CDI diagnosis to death. CDI prevention should be primarily focused on hospitalised elderly people receiving antibiotics. WBC, neutrophil count, CRP, creatinine, albumin and lactate levels should be tested in every hospitalised patient treated for CDI to assess the risk of a fatal outcome.
Published: 2021

7. Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations

Author: Mario Bo, Ferdinando Varbella, Wojciech Wańha, Ovidio De Filippo, Giuseppe Venuti, Federico Conrotto, Bernardo Cortese, Carlo Di Mario, Filippo Figini, Guglielmo Gallone, Nicola Ryan, Francesco Piroli, Iván J. Núñez-Gil, Saverio Muscoli, Imad Sheiban, Mauro Pennacchi, Andrea Rognoni, Javier Escaned, Alessio Mattesini, Francesco Burzotta, Zenon Huczek, Gaetano M. De Ferrari, Daniela Trabattoni, Wojciech Wojakowski, Imori Yoichi, Pier Paolo Bocchino, Andrea Montabone, Giorgio Quadri, Francesco Costa, Fabrizio D'Ascenzo, Giacomo Boccuzzi, Davide Capodanno, Enrico Cerrato, Gérard Helft, Grzegorz Smolka, Radosław Parma, Cristina Rolfo, Alaide Chieffo, Satoru Mitomo, Università degli studi di Torino = University of Turin (UNITO), Università degli Studi di Messina = University of Messina (UniMe), University of Catania [Italy], University of Rome 'Tor Vergeta', Università degli Studi di Roma Tor Vergata [Roma], IRCCS Ospedale San Raffaele [Milan, Italy], Nippon Medical School [Tokyo, Japon], Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Ospedale di Rivoli [Rivoli, Italy] (OR), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Medical University of Silesia (SUM), Medical University of Warsaw - Poland, Ospedale San Giovanni Bosco [Turin, Italy] (OSGB), University Hospital 'Maggiore della Carità' [Novara, Italy], Clinica Pederzoli [Peschiera del Garda, Italy] (CP), Careggi University Hospital [Florence, Italie], ASST Fatebenefratelli-Sacco [Milan, Italy], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), and Lesnik, Philippe
Subjects: medicine.medical_specialty, medicine.medical_treatment, left main, [SDV]Life Sciences [q-bio], Coronary Artery Disease, risk stratification, 030204 cardiovascular system & hematology, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Risk Factors, Internal medicine, Humans, Medicine, Radiology, Nuclear Medicine and imaging, In patient, cardiovascular diseases, 030212 general & internal medicine, Myocardial infarction, Target lesion revascularization, Framingham Risk Score, business.industry, bifurcation, dual antiplatelet therapy, Percutaneous coronary intervention, Stent, Drug-Eluting Stents, General Medicine, medicine.disease, [SDV] Life Sciences [q-bio], Treatment Outcome, surgical procedures, operative, Conventional PCI, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Cardiology, Stents, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors, Mace
Abstract: International audience; Background: The PARIS risk score (PARIS-rs) and percutaneous coronary intervention complexity (PCI-c) predict clinical and procedural residual ischemic risk following PCI. Their accuracy in patients undergoing unprotected left main (ULM) or bifurcation PCI has not been assessed.Methods: The predictive performances of the PARIS-rs (categorized as low, intermediate, and high) and PCI-c (according to guideline-endorsed criteria) were evaluated in 3,002 patients undergoing ULM/bifurcation PCI with very thin strut stents.Results: After 16 (12-22) months, increasing PARIS-rs (8.8% vs. 14.1% vs. 27.4%, p < .001) and PCI-c (15.2% vs. 11%, p = .025) were associated with higher rates of major adverse cardiac events ([MACE], a composite of death, myocardial infarction [MI], and target vessel revascularization), driven by MI/death for PARIS-rs and target lesion revascularization/stent thrombosis for PCI-c (area under the curves for MACE: PARIS-rs 0.60 vs. PCI-c 0.52, p-for-difference < .001). PCI-c accuracy for MACE was higher in low-clinical-risk patients; while PARIS-rs was more accurate in low-procedural-risk patients. ≥12-month dual antiplatelet therapy (DAPT) was associated with a lower MACE rate in high PARIS-rs patients, (adjusted-hazard ratio 0.42 [95% CI: 0.22-0.83], p = .012), with no benefit in low to intermediate PARIS-rs patients. No incremental benefit with longer DAPT was observed in complex PCI.Conclusions: In the setting of ULM/bifurcation PCI, the residual ischemic risk is better predicted by a clinical risk estimator than by PCI complexity, which rather appears to reflect stent/procedure-related events. Careful procedural risk estimation is warranted in patients at low clinical risk, where PCI complexity may substantially contribute to the overall residual ischemic risk.
Published: 2021

8. Determinants of therapeutic lag in multiple sclerosis

Author: Tomas Kalincik, Marc Girard, Corinne Pottier, Murat Terzi, Jean Pelletier, Oliver Gerlach, Julie Prevost, Dana Horakova, Francois Grand'Maison, Raed Alroughani, Guillermo Izquierdo, Francesco Patti, Federico Frascoli, Maria Trojano, Franco Granella, Pamela A. McCombe, Charles B Malpas, Recai Turkoglu, Aurélie Ruet, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Helmut Butzkueven, Pierre Clavelou, Tamara Castillo Trivino, Marco Onofrj, Jean Philippe Camdessanche, Pierre Labauge, Vincent Van Pesch, Pierre Grammond, Abir Wahab, Roberto Bergamaschi, Aysun Soysal, Diana Ferraro, Bertrand Bourre, Olivier Gout, Jeannette Lechner-Scott, Sara Eichau, Emmanuelle Leray, Alexis Montcuquet, Pierre Duquette, Olivier Casez, Youssef Sidhom, Patrizia Sola, Bart Van Wijmeersch, Izanne Roos, Gilles Edan, Serkan Ozakbas, David Laplaud, Sandra Vukusic, Abdullatif Al Khedr, Céline Labeyrie, Philippe Cabre, Eric Thouvenot, Céline Louapre, Romain Casey, Alessandra Lugaresi, Riadh Gouider, Alasdair Coles, Eric Berger, Ivania Patry, Gerardo Iuliano, Elisabetta Cartechini, Cavit Boz, Karolina Hankiewicz, Eva Havrdova, Eduardo Aguera-Morales, J William L Brown, Jérôme De Seze, Bruno Stankoff, Olivier Heinzlef, Gilles Defer, Alexandre Prat, Chantal Nifle, Maria José Sá, Marc Debouverie, Daniele Spitaleri, Aude Maurousset, Thibault Moreau, Christine Lebrun-Frenay, Hélène Zéphir, University of Melbourne, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Collectif de recherche handicap, autonomie et société inclusive (CoRHASI), Swinburne University of Technology [Melbourne], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Charles University [Prague], Università degli studi di Catania [Catania], Università degli studi 'G. d'Annunzio' Chieti-Pescara [Chieti-Pescara] (Ud'A), Università degli Studi di Modena e Reggio Emilia (UNIMORE), University of Queensland [Brisbane], Monash University [Clayton], UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Charles University [Prague] (CU), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), University of Bari Aldo Moro (UNIBA), University of Catania [Italy], Hospital Virgen Macarena, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), CHU Toulouse [Toulouse], INSERM, Neurocentre Magendie, U1215, Physiopathologie de la Plasticité Neuronale, F-33000 Bordeaux, France, CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] (DEÜ), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, Fernando Pessoa University, Azienda Ospedaleria Universitaria di Modena, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Nice (CHU Nice), Karadeniz Technical University (KTU), Università degli Studi di Macerata = University of Macerata (UNIMC), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), University of Newcastle [Australia] (UoN), Zuyderland Hospital [Heerlen, The Netherlands], Ondokuz Mayis University, University of Parma = Università degli studi di Parma [Parme, Italie], Amiri hospital, University of Salerno (UNISA), Université Catholique de Louvain = Catholic University of Louvain (UCL), Hasselt University (UHasselt), San Giuseppe Moscati Hospital [Avellino, Italie], Bakirkoy Matern & Childrens State Hosp, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Universidad de Córdoba [Cordoba], Hospital Donostia, CHU Clermont-Ferrand, Hôpital de la Timone [CHU - APHM] (TIMONE), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CHI Poissy-Saint-Germain, Université de la Manouba [Tunisie] (UMA), University of Debrecen, Hôpital Charles Nicolle [Rouen], CHU Amiens-Picardie, CHU de la Martinique [Fort de France], CHU Limoges, CHU Henri Mondor, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre Hospitalier Sud Francilien, CH Evry-Corbeil, Centre Hospitalier de Saint-Denis [Ile-de-France], Centre Hospitalier René Dubos [Pontoise], This study was supported by the EDMUS Foundation and NHMRC [1140766,1129189, 1157717]. IR is supported by a MSIF-ARSEP McDonald fellowship grantand a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profitorganization that receives support from Biogen, Novartis, Merck, Roche, Teva andSanofi Genzyme. The study was conducted separately and apart from the guidanceof the sponsors. The Observatoire Français de la Sclérose en Plaques (OFSEP) issupported by a grant provided by the French State and handled by the 'AgenceNationale de la Recherche,' within the framework of the 'Investments for the Future'program, under the reference ANR-10-COHO-002, by the Eugène Devic EDMUSFoundation against multiple sclerosis and by the ARSEP Foundation., ANR-10-COHO-0002,OFSEP,Observatoire Français de la Sclérose en Plaques(2010), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Roos I., Leray E., Frascoli F., Casey R., Brown J.W.L., Horakova D., Havrdova E.K., Debouverie M., Trojano M., Patti F., Izquierdo G., Eichau S., Edan G., Prat A., Girard M., Duquette P., Onofrj M., Lugaresi A., Grammond P., Ciron J., Ruet A., Ozakbas S., De Seze J., Louapre C., Zephir H., Sa M.J., Sola P., Ferraro D., Labauge P., Defer G., Bergamaschi R., Lebrun-Frenay C., Boz C., Cartechini E., Moreau T., Laplaud D., Lechner-Scott J., Grand'Maison F., Gerlach O., Terzi M., Granella F., Alroughani R., Iuliano G., Van Pesch V., Van Wijmeersch B., Spitaleri D.L.A., Soysal A., Berger E., Prevost J., Aguera-Morales E., McCombe P., Castillo Trivino T., Clavelou P., Pelletier J., Turkoglu R., Stankoff B., Gout O., Thouvenot E., Heinzlef O., Sidhom Y., Gouider R., Csepany T., Bourre B., Al Khedr A., Casez O., Cabre P., Montcuquet A., Wahab A., Camdessanche J.-P., Maurousset A., Patry I., Hankiewicz K., Pottier C., Maubeuge N., Labeyrie C., Nifle C., Coles A., Malpas C.B., Vukusic S., Butzkueven H., Kalincik T., Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Università degli studi di Catania = University of Catania (Unict), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), University of Newcastle [Callaghan, Australia] (UoN), Ondokuz Mayis University (OMU), Università degli studi di Parma = University of Parma (UNIPR), Universidad de Córdoba = University of Córdoba [Córdoba], University of Debrecen Egyetem [Debrecen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), CHU Henri Mondor [Créteil], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Registrie, Male, medicine.medical_specialty, Treatment response, Pediatrics, Neurology, Lag, [SDV]Life Sciences [q-bio], Aucun, multiple sclerosis, 03 medical and health sciences, Disability Evaluation, 0302 clinical medicine, Multiple Sclerosis, Relapsing-Remitting, Recurrence, medicine, Humans, Treatment effect, Disabled Persons, Registries, 030304 developmental biology, 0303 health sciences, business.industry, Multiple sclerosis, Delayed onset, medicine.disease, 3. Good health, Clinical neurology, therapeutic lag, multiple sclerosi, Disease Progression, Disabled Person, Observational study, Female, observational study, Neurology (clinical), business, 030217 neurology & neurosurgery, Human
Abstract: International audience; Objective: To explore the associations of patient and disease characteristics with the duration of therapeutic lag for relapses and disability progression.Background: Therapeutic lag represents the delay from initiation of therapy to attainment of full treatment effect. Understanding the determinants of therapeutic lag provides valuable information for personalised choice of therapy in multiple sclerosis (MS).Design/Methods: Data from MSBase, a multinational MS registry, and OFSEP, the French national registry, were used. Patients diagnosed with MS, minimum 1-year exposure to MS treatment, minimum 3-year pre-treatment follow up and yearly review were included in the analysis. By studying incidence of relapses and 6-month confirmed disability progression, the duration of therapeutic lag was calculated by identifying the first local minimum of the first derivative after treatment start in subgroups stratified by patient and disease characteristics. Pairwise analyses of univariate predictors were performed. Combinations of determinants that consistently drove differences in therapeutic lag in pair by pair analyses were included in the final model.Results: Baseline EDSS, ARR and sex were associated with duration of therapeutic lag on disability progression in univariate and pairwise bivariable analyses. In the final model, therapeutic lag was 27.8 weeks shorter in females with ARR6 compared to those with EDSS>=6 (26.6, 18.2–34.9 vs 54.3, 47.2–61.5). Baseline EDSS, ARR, sex and MS phenotype were associated with duration of therapeutic lag on relapses in univariate analyses. Pairwise bivariable analyses of the pairs of determinants suggested ependently associated with therapeutic lag. In the final model, therapeutic lag was shortest in those with RRMS and EDSS
Published: 2021

9. Insect-Inspired Robots: Bridging Biological and Artificial Systems

Author: Ilya Brodoline, Julien Dupeyroux, Xiaofeng Xiong, Poramate Manoonpong, Julien Serres, Stéphane Viollet, Luca Patané, Paolo Arena, University of Southern Denmark (SDU), Vidyasirimedhi Institute of Science and Technology, University of Messina, Institut des Sciences du Mouvement Etienne Jules Marey (ISM), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Aix Marseille Université (AMU), Delft University of Technology (TU Delft), Centre National de la Recherche Scientifique (CNRS), University of Catania [Italy], This work was funded with the help of the Centre National de la Recherche Scientifique (CNRS) in the framework of the MiMiC-ANT project subsidized by the PEPS INSIS 2020 'Ingénierieinspirée par la nature' program. P.M. acknowledges support from the Human Frontier Science Program under grant agreement no. RGP0002/2017, from Vidyasirimedhi Institute of Science andTechnology (VISTEC) research funding on Bio-inspired Robotics. X.X. acknowledges support from the Brødrene Hartmanns and Thomas B. Thriges under grant agreements A36775 and 7648-2106., Vidyasirimedhi Institute of Science and Technology [Thaïlande] (VISTEC), and Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: biomimetism, Bionics, biomimicry, Insecta, This review article aims to address common research questions in hexapod robotics. How can we build intelligent autonomous hexapod robots that can exploit their biomechanics, This review article aims to address common research questions in hexapod robotics. How can we build intelligent autonomous hexapod robots that can exploit their biomechanics, morphology, and computational systems, to achieve autonomy, adaptability, and energy efficiency comparable to small living creatures, such as insects? Are insects good models for building such intelligent hexapod robots because they are the only animals with six legs? This review article is divided into three main sections to address these questions, as well as to assist roboticists in identifying relevant and future directions in the field of hexapod robotics over the next decade. After an introduction in section (1), the sections will respectively cover the following three key areas: (2) biomechanics focused on the design of smart legs, (3) locomotion control, and (4) high-level cognition control. These interconnected and interdependent areas are all crucial to improving the level of performance of hexapod robotics in terms of energy efficiency, terrain adaptability, autonomy, and operational range. We will also discuss how the next generation of bioroboticists will be able to transfer knowledge from biology to robotics and vice versa, such as insects? Are insects good models for building such intelligent hexapod robots because they are the only animals with six legs? This review article is divided into three main sections to address these questions, Review, Biochemistry, Field (computer science), Biomimetism, Analytical Chemistry, [SPI]Engineering Sciences [physics], 0302 clinical medicine, Human–computer interaction, morphology, as well as to assist roboticists in identifying relevant and future directions in the field of hexapod robotics over the next decade. After an introduction in section (1), Instrumentation, media_common, 0303 health sciences, Robotics, Legged robotics, Atomic and Molecular Physics, and Optics, Biomechanical Phenomena, and computational systems, and energy efficiency comparable to small living creatures, biorobotics, to achieve autonomy, legged robotics, Locomotion, Exploit, and (4) high-level cognition control. These interconnected and interdependent areas are all crucial to improving the level of performance of hexapod robotics in terms of energy efficiency, media_common.quotation_subject, terrain adaptability, TP1-1185, hexapod, Adaptability, [SPI.AUTO]Engineering Sciences [physics]/Automatic, Biomimicry, Biorobotics, Hexapod, 03 medical and health sciences, the sections will respectively cover the following three key areas: (2) biomechanics focused on the design of smart legs, Animals, Electrical and Electronic Engineering, autonomy, 030304 developmental biology, business.industry, Chemical technology, [SCCO.NEUR]Cognitive science/Neuroscience, adaptability, and operational range. We will also discuss how the next generation of bioroboticists will be able to transfer knowledge from biology to robotics and vice versa, Robot, Artificial intelligence, bionics, business, 030217 neurology & neurosurgery
Abstract: International audience; This review article aims to address common research questions in hexapod robotics. How can we build intelligent autonomous hexapod robots that can exploit their biomechanics, morphology,and computational systems, to achieve autonomy, adaptability, and energy efficiency comparable to small living creatures, such as insects? Are insects good models for building such intelligenthexapod robots because they are the only animals with six legs? This review article is divided into three main sections to address these questions, as well as to assist roboticists in identifying relevant and future directions in the field of hexapod robotics over the next decade. After an introduction in section (1), the sections will respectively cover the following three key areas: (2) biomechanics focused on the design of smart legs; (3) locomotion control; and (4) high-level cognition control. These interconnected and interdependent areas are all crucial to improving the level of performance ofhexapod robotics in terms of energy efficiency, terrain adaptability, autonomy, and operational range. We will also discuss how the next generation of bioroboticists will be able to transfer knowledge from biology to robotics and vice versa.
Published: 2021

10. Recent advances toward the sustainable management of invasive Xylosandrus ambrosia beetles

Author: You Li, Daniel Carrillo, Davide Rassati, Nicolas Meurisse, J.P. Egonyu, Christopher M. Ranger, Peter H. W. Biedermann, Antonio Biondi, Louela A. Castrillo, Lukasz L. Stelinski, Hisashi Kajimura, Antonio Gugliuzzo, Naoto Kamata, Jason B. Oliver, Roanne Sutherland, Jiri Hulcr, Khalid Haddi, Giovanna Tropea Garzia, Hervé Jactel, Mark G. Wright, D. Gallego, Universidad de Alicante. Departamento de Ecología, University of Catania [Italy], University of Freiburg [Freiburg], University of Florida [Gainesville] (UF), United States Department of Agriculture (USDA), International Centre of Insect Physiology and Ecology (ICIPE), ICIPE, Universidad de Alicante, Federal University of Lavras, Biodiversité, Gènes & Communautés (BioGeCo), Université de Bordeaux (UB)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Nagoya City University [Nagoya, Japan], The University of Tokyo (UTokyo), New Zealand Forest Research Institute, SCION, Tennessee State University, USDA Agricultural Research Service [Maricopa, AZ] (USDA), DAFNAE, Universita degli Studi di Padova, and University of Hawai‘i [Mānoa] (UHM)
Subjects: 0106 biological sciences, Integrated pest management, Ambrosia fungi, Biological pest control, 010603 evolutionary biology, 01 natural sciences, Invasive species, Xyleborini, Forest health, biology, business.industry, Agroforestry, Xylosandrus compactus, fungi, Pest control, Ecología, 15. Life on land, biology.organism_classification, Scolytinae, 010602 entomology, Curculionidae, [SDE]Environmental Sciences, business, Agronomy and Crop Science
Abstract: We provide an overview of both traditional and innovative control tools for management of three Xylosandrus ambrosia beetles (Coleoptera: Curculionidae: Scolytinae), invasive species with a history of damage in forests, nurseries, orchards and urban areas. Xylosandrus compactus, X. crassiusculus and X. germanus are native to Asia, and currently established in several countries around the globe. Adult females bore galleries into the plant xylem inoculating mutualistic ambrosia fungi that serve as food source for the developing progeny. Tunneling activity results in chewed wood extrusion from entry holes, sap outflow, foliage wilting followed by canopy dieback, and branch and trunk necrosis. Maintaining plant health by reducing physiological stress is the first recommendation for long-term control. Baited traps, ethanol-treated bolts, trap logs and trap trees of selected species can be used to monitor Xylosandrus species. Conventional pest control methods are mostly ineffective against Xylosandrus beetles because of the pests’ broad host range and rapid spread. Due to challenges with conventional control, more innovative control approaches are being tested, such as the optimization of the push–pull strategy based on specific attractant and repellent combinations, or the use of insecticide-treated netting. Biological control based on the release of entomopathogenic and mycoparasitic fungi, as well as the use of antagonistic bacteria, has yielded promising results. However, these technologies still require validation in real field conditions. Overall, we suggest that management efforts should primarily focus on reducing plant stress and potentially be combined with a multi-faceted approach for controlling Xylosandrus damage. This research was supported by the University of Catania (Project Emergent Pests and Pathogens and Relative Sustainable Strategies - 5A722192113; PhD fellowship to AG). P.H.W.B. was supported by the German Research Foundation (DFG Emmy Noether Grant BI 1956/1–1). Funding to MGW: USDA-NIFA, ARS and APHIS; ISDA Hatch; Hawaii Dept. of Agriculture. JH and YL were funded by the USDA APHIS and USDA Forest Service. HK was partially supported by Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research, KAKENHI, Nos. 18KK0180, 19H02994 and 20H03026). KH was partially supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes, Brazil; Finance code 001). Open access funding provided by Università degli Studi di Catania within the CRUI-CARE Agreement.
Published: 2021

11. Impact of stent thickness on clinical outcomes in small vessel and bifurcation lesions: a RAIN-CARDIOGROUP VII sub-study

Author: Ovidio De Filippo, Wojciech Wańha, Satoru Mitomo, Nicola Ryan, Radosław Parma, Imad Sheiban, Luca Franchin, Giuseppe Venuti, Bernardo Cortese, Francesco Piroli, Gérard Helft, Iván J. Núñez-Gil, Andrea Montabone, Andrea Rognoni, Saverio Muscoli, Yoichi Imori, Zenon Huczek, Giorgio Quadri, Ferdinando Varbella, Daniela Trabattoni, Gaetano M. De Ferrari, Fabrizio D'Ascenzo, Wojciech Wojakowski, Filippo Figini, Università degli studi di Torino = University of Turin (UNITO), Clínico San Carlos University Hospital, Medical University of Silesia (SUM), Nippon Medical School [Tokyo, Japon], Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano = University of Milan (UNIMI)-Università degli Studi di Milano = University of Milan (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Medical University of Warsaw - Poland, AOU Policlinico Vittorio-Emanuele [Catania, Italia], University of Catania [Italy], Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy, Ospedale San Giovanni Bosco [Turin, Italy] (OSGB), University Hospital 'Maggiore della Carità' [Novara, Italy], Clinica Pederzoli [Peschiera del Garda, Italy] (CP), IRCCS Ospedale San Raffaele [Milan, Italy], Ospedale 'Infermi' di Rimini [Rimini, Italy] (OIR), Azienda Ospedaliero-Universitaria San Luigi Gonzaga/San Luigi Gonzaga University Hospital (SLGUH), Clinica San Carlo [Milan, Italy] (CSC), Institut de cardiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Lesnik, Philippe
Subjects: Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Population, Coronary Artery Disease, 030204 cardiovascular system & hematology, Prosthesis Design, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Percutaneous Coronary Intervention, Risk Factors, Internal medicine, medicine, Clinical endpoint, Humans, cardiovascular diseases, 030212 general & internal medicine, Myocardial infarction, education, Aged, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Coronary Thrombosis, Hazard ratio, Stent, General Medicine, Middle Aged, medicine.disease, [SDV] Life Sciences [q-bio], Treatment Outcome, Italy, Conventional PCI, Cardiology, Female, Stents, Small vessel, Cardiology and Cardiovascular Medicine, business, Mace
Abstract: Background The clinical impact of stent strut thickness in coronary bifurcation lesions in small vessels has not been assessed in a real-world population. Methods and results All 506 patients enrolled in the RAIN study, undergoing PCI in a vessel with a diameter 2.5 mm or less were retrospectively evaluated and divided into two groups according to stent strut thickness: 74 μm (n = 206) versus 81 μm (n = 300); 87.1% of the lesions involved bifurcations. TLF [defined as a composite of myocardial infarction (MI) and target lesion revascularization (TLR)] was the primary endpoint, with MACE (a composite of death, MI and TLR), its components and stent thrombosis the secondary endpoint. After 16 (14-18) months, a lower incidence of TLF (4.3 vs. 9.8%, P = 0.026) and ST (1.0 vs. 3.0%, P = 0.042) was seen in the 74 μm group, whereas MACE occurred in 60 of 506 patients, with no statistical difference between the two groups (9.7 vs. 13.3%, P = 0.070). At multivariate analysis, chronic renal failure increased the risk of TLF while thinner strut was an independent protective factor (hazard ratio 0.51, CI 0.17-0.85, P = 0.005). Conclusion In this real-world population, patients being treated for small vessels lesions with thinner strut stents had lower rates of TLF, MI and ST.
Published: 2021

12. Prevalence of idiopathic REM behavior disorder: a systematic review and meta-analysis

Author: Loretta Giuliano, Alessandra Nicoletti, Pierre-Marie Preux, Mario Zappia, Jaime Luna, Calogero Edoardo Cicero, University of Catania [Italy], Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, and Université de Limoges (UNILIM)
Subjects: medicine.medical_specialty, Population, prevalence, Subgroup analysis, REM Sleep Behavior Disorder, REM sleep behavior disorder, 03 medical and health sciences, 0302 clinical medicine, Physiology (medical), Internal medicine, Epidemiology, medicine, Humans, education, 030304 developmental biology, REM behavior disorder, 0303 health sciences, education.field_of_study, business.industry, Ecological study, medicine.disease, Confidence interval, 3. Good health, meta-analysis, Sample size determination, Meta-analysis, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, epidemiology, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Study Objectives To provide an overall estimate of the prevalence of idiopathic REM Sleep Behavior Disorder (iRBD). Methods Two investigators have independently searched the PubMed and Scopus databases for population-based studies assessing the prevalence of iRBD. Data about type of diagnosis (polysomnographic diagnosis, defined iRBD [dRBD]; clinical diagnosis, probable RBD [pRBD]), continent, age range of the screened population, quality of the studies, sample size, screening questionnaires, and strategies have been gathered. A random-effect model was used to estimate the pooled prevalence. Heterogeneity was investigated with subgroup analysis and meta-regression. Results From 857 articles found in the databases, 19 articles were selected for the systematic review and meta-analysis. According to the type of diagnosis, five studies identified dRBD cases given a pooled prevalence of 0.68% (95% confidence interval [CI] 0.38–1.05) without significant heterogeneity (Cochran’s Q p = 0.11; I2 = 46.43%). Fourteen studies assessed the prevalence of pRBD with a pooled estimate of 5.65% (95% CI 4.29–7.18) and a significant heterogeneity among the studies (Cochran’s Q p < 0.001; I2 = 98.21%). At the subgroup analysis, significant differences in terms of prevalence were present according to the quality of the studies and, after removing two outlaying studies, according to the continents and the screening questionnaire used. Meta-regression did not identify any significant effect of the covariates on the pooled estimates. Conclusion Prevalence estimates of iRBD are significantly impacted by diagnostic level of certainty. Variations in pRBD prevalence are due to methodological differences in study design and screening questionnaires employed.
Published: 2021

13. COVID-19-related echocardiographic patterns of cardiovascular dysfunction in critically ill patients: A systematic review of the current literature

Author: Katerina Negri, Filippo Sanfilippo, Angelo Milani, Marinella Astuto, Manuel Ignacio Monge García, Antonio Messina, Antoine Vieillard-Baron, Maurizio Cecconi, Lorenzo Calabrò, Humanitas University [Milan] (Hunimed), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], University of Milan, University of Catania [Italy], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, and Hôpital Ambroise Paré [AP-HP]
Subjects: Adult, 2019-20 coronavirus outbreak, medicine.medical_specialty, Diastolic function, Coronavirus disease 2019 (COVID-19), Critical Illness, [SDV]Life Sciences [q-bio], Disease, Critical Care and Intensive Care Medicine, Article, SARS-CoV-2, severe disease with the acute respiratory syndrome, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, EF, ejection fraction, Medicine, Prospective Studies, Trial registration, Retrospective Studies, COVID-19, coronavirus disease 2019, GLS, global longitudinal strain, Ejection fraction, SARS-CoV-2, business.industry, Critically ill, Systolic function, COVID-19, 030208 emergency & critical care medicine, Retrospective cohort study, Left ventricle, ICU, intensive care unit, 3. Good health, RV, right ventricle, Critical care, LV, left ventricle, 030228 respiratory system, Sample size determination, Echocardiography, TAPSE, Tricuspid Annular Plane Systolic Excursion, Right ventricle, business
Abstract: International audience; Purpose: Coronavirus disease 2019 (COVID-19) infection may trigger a multi-systemic disease involving different organs. There has been growing interest regarding the harmful effects of COVID-19 on the cardiovascular system. This systematic review aims to systematically analyze papers reporting echocardiographic findings in hospitalized COVID-19 subjects. Materials and methods: We included prospective and retrospective studies reporting echocardiography data in >10 hospitalized adult subjects with COVID-19; from 1st February 2020 to 15th January 2021. Results: The primary electronic search identified 1120 articles. Twenty-nine studies were finally included, enrolling 3944 subjects. Overall the studies included a median of 68.0% (45.5–100.0) of patients admitted to ICU. Ten studies (34.4%) were retrospective, and 20 (68.9%) single-centred. Overall enrolling 1367 subjects, three studies reported normal echocardiographic findings in 49 ± 18% of cases. Seven studies (24.1%) analyzed the association between echocardiographic findings and mortality, mostly related to right ventricular (RV) dysfunction. Conclusions: Data regarding the use of echocardiography on hospitalized, predominantly ICU, COVID-19 patients were retrieved from studies with heterogeneous designs, variable sample sizes, and severity scores. Normal echocardiographic findings were reported in about 50% of subjects, with LVEF usually not affected. Overall, RV dysfunction seems more likely associated with increased mortality. Trial Registration: CRD42020218439.
Published: 2021

14. Sperm Vitality and Necrozoospermia: Diagnosis, Management, and Results of a Global Survey of Clinical Practice

Author: Yoshiharu Morimoto, Kasonde Bowa, Israel Maldonado Rosas, Marjan Sabbaghian, Ralf Henkel, Juan Manuel Corral Molina, Chak-Lam Cho, Kristian Leisegang, Hisanori Taniguchi, Mohamed Ali Sadighi Gilani, Germar-Michael Pinggera, Sunil Jindal, Christopher Chee Kong Ho, Gianmaria Salvio, Marlon Martinez, Juan Carlos Alvarez, Taha A. Abdel-Meguid, Jean de la Rosette, Taymour Mostafa, Mohamed S. Al-Marhoon, Sava Micic, Ashok Agarwal, Jonathan Ramsay, Samantha B. Schon, Ala'a Farkouh, Kareim Khalafalla, Gian Maria Busetto, Nicholas N. Tadros, Sajal Gupta, Edoardo Pescatori, Gökhan Çeker, Renata Finelli, Ayad Palani, Damayanthi Durairajanayagam, Marcelo Gabriel Rodriguez, Florence Boitrelle, Rupin Shah, Eric Chung, Mohamed Arafa, Ramadan A Saleh, Christina Anagnostopoulou, Shinnosuke Kuroda, Parviz Kavoussi, Shinichiro Fukuhara, Armand Zini, Giovanni M. Colpi, Paraskevi Vogiatzi, Neel Parekh, Hussein Kandil, Tan V. Le, Raghavender Kosgi, Ponco Birowo, Rossella Cannarella, Giancarlo Balercia, Mara Simopoulou, Sijo Parekattil, Ettore Caroppo, Aldo E. Calogero, Mesut Berkan Duran, Osvaldo Rajmil, Amarnath Rambhatla, Haitham Elbardisi, Hyun Jun Park, Saleem Ali Banihani, Fotios Dimitriadis, Edmund Y. Ko, Rakesh Sharma, Cleveland Clinic, CHI Poissy-Saint-Germain, Biologie de la Reproduction, Environnement, Epigénétique & Développement (BREED), École nationale vétérinaire d'Alfort (ENVA)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hamad Medical Corporation [Doha, Qatar], Weill Cornell Medicine [Qatar], The Chinese University of Hong Kong [Hong Kong], Henry Ford Health System, Imperial College London, University of the Western Cape, The University of Texas at San Antonio (UTSA), Loma Linda University, Fakih IVF Fertility Center, University of Garmian, Università Politecnica delle Marche [Ancona] (UNIVPM), Cairo University - Faculty of Medicine, Fundació Puigvert [Barcelona, Spain], Jordan University of Science and Technology [Irbid, Jordan], University of Michigan Medical School [Ann Arbor], University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Pham Ngoc Thach Medical University [Ho Chi Minh city, Vietnam] (PNTUM), Faculty of Medicine [Jakarta, Indonesia], Universitas Indonesia [Jakarta, Indonesia], Taylor's University Malaysia, University of Catania [Italy], Hamad medical corporation, McGill University = Université McGill [Montréal, Canada], University of Queensland [Brisbane], Aristotle University of Thessaloniki, Innsbruck Medical University [Austria] (IMU), Università degli Studi di Foggia - University of Foggia, Kansai Medical University, Pusan National University, Hammersmith Hospital NHS Imperial College Healthcare, National and Kapodistrian University of Athens (NKUA), Royan Institute for Reproductive Biomedicine [Tehran, Iran], UNIVERSITY OF SANTO TOMAS MANILA PHL, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Sultan Qaboos University (SQU), Università degli studi di Catania [Catania], Osaka University [Osaka], University of Central Florida [Orlando] (UCF), Minia University, King Abdulaziz University, and Lilavati Hospital and Research Centre
Subjects: Aging, Vitality, 0302 clinical medicine, Pharmacology (medical), TESTICULAR SPERMATOZOA, Andrology, Sperm motility, 0303 health sciences, 030219 obstetrics & reproductive medicine, Spermatozoon, Health Policy, Urology & Nephrology, Spermatozoa, 3. Good health, Psychiatry and Mental health, medicine.anatomical_structure, Asthenozoospermia, EosineYellowish-(YS), Eosine Yellowish-(YS), Life Sciences & Biomedicine, Infertility, medicine.medical_specialty, endocrine system, Urology, Semen, ICSI, PARAMETERS, 03 medical and health sciences, Endocrinology & Metabolism, medicine, Intensive care medicine, 030304 developmental biology, Nigrosin, Science & Technology, SEMINAL PLASMA, business.industry, urogenital system, MALE-INFERTILITY, Public Health, Environmental and Occupational Health, [SDV.BDLR]Life Sciences [q-bio]/Reproductive Biology, medicine.disease, Sperm, VIABILITY, IMMOTILE, Health Care Sciences & Services, Reproductive Medicine, DNA-DAMAGE, SEMEN QUALITY, Etiology, business, HYPOOSMOTIC SWELLING TEST
Abstract: International audience; Sperm vitality testing is a basic semen examination that has been described in the World Health Organization (WHO) Laboratory Manual for the Examination and Processing of Human Semen from its primary edition, 40 years ago. Several methods can be used to test sperm vitality, such as the eosin-nigrosin (E-N) stain or the hypoosmotic swelling (HOS) test. In the 6th (2021) edition of the WHO Laboratory Manual, sperm vitality assessment is mainly recommended if the total motility is less than 40%. Hence, a motile spermatozoon is considered alive, however, in certain conditions an immotile spermatozoon can also be alive. Therefore, the differentiation between asthenozoospermia (pathological decrease in sperm motility) and necrozoospermia (pathological decrease in sperm vitality) is important in directing further investigation and management of infertile patients. The causes leading to necrozoospermia are diverse and can either be local or general, testicular or extra-testicular. The andrological management of necrozoospermia depends on its etiology. However, there is no standardized treatment available presently and practice varies among clinicians. In this study, we report the results of a global survey to understand current practices regarding the physician order of sperm vitality tests as well as the management practices for necrozoospermia. Laboratory and clinical scenarios are presented to guide the reader in the management of necrozoospermia with the overall objective of establishing a benchmark ranging from the diagnosis of necrozoospermia by sperm vitality testing to its clinical management.
Published: 2021

15. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Author: Mark Slee, Guillermo Izquierdo, Per Soelberg Soerensen, Karen Schreiber, Alexandre Prat, Francois Grand'Maison, Maria Trojano, Franco Granella, Pierre Duquette, David Laplaud, Elisabeth Maillart, Henrik Kahr Mathiesen, Bassem Yamout, Cavit Boz, Jean Pelletier, Corinne Pottier, Jette L. Frederiksen, Claudia Christina Pfleger, Tomas Kalincik, Olivier Gout, Daniele Spitaleri, Marc Girard, Marco Onofrj, Jérôme De Seze, Helmut Butzkueven, Emmanuelle Leray, Philippe Cabre, Julie Prevost, Abullatif Al-Khedr, Aude Maurousset, Eric Berger, Sifat Sharmin, Ivania Patry, Pamela A. McCombe, Patrizia Sola, Olga Skibina, Diana Ferraro, Pierre Clavelou, Francesco Patti, Finn Sellebjerg, Niels Koch-Henriksen, Alexis Montcuquet, Recai Turkoglu, Romain Casey, Bart Van Wijmeersch, Hélène Zéphir, Pierre Grammond, Dana Horakova, Davide Maimone, Serkan Ozakbas, Céline Labeyrie, Murat Terzi, Aurélie Ruet, Steve Vucic, Jonathan Ciron, Tünde Csépány, Nicolas Maubeuge, Bruno Stankoff, Mathilde Lefort, Katherine Buzzard, Karolina Hankiewicz, Jean-Philippe Camdessanché, Raed Alroughani, Michael Broksgaard Jensen, Pierre Labauge, Olivier Casez, Peter Vestergaard Rasmussen, Bertrand Bourre, Olivier Heinzlef, Gilles Defer, Gilles Edan, Alessandra Lugaresi, Abir Wahab, Melinda Magyari, Anneke van der Walt, Eva Havrdova, Johanna Balslev Andersen, Chantal Nifle, Stephan Bramow, Marc Debouverie, Thibault Moreau, Sandra Vukusic, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Eric Thouvenot, Sharmin S., Lefort M., Andersen J.B., Leray E., Horakova D., Havrdova E.K., Alroughani R., Izquierdo G., Ozakbas S., Patti F., Onofrj M., Lugaresi A., Terzi M., Grammond P., Grand'Maison F., Yamout B., Prat A., Girard M., Duquette P., Boz C., Trojano M., McCombe P., Slee M., Lechner-Scott J., Turkoglu R., Sola P., Ferraro D., Granella F., Prevost J., Maimone D., Skibina O., Buzzard K., Van der Walt A., Van Wijmeersch B., Csepany T., Spitaleri D., Vucic S., Casey R., Debouverie M., Edan G., Ciron J., Ruet A., De Seze J., Maillart E., Zephir H., Labauge P., Defer G., Lebrun-Frenay C., Moreau T., Berger E., Clavelou P., Pelletier J., Stankoff B., Gout O., Thouvenot E., Heinzlef O., Al-Khedr A., Bourre B., Casez O., Cabre P., Montcuquet A., Wahab A., Camdessanche J.-P., Maurousset A., Patry I., Hankiewicz K., Pottier C., Maubeuge N., Labeyrie C., Nifle C., Laplaud D., Koch-Henriksen N., Sellebjerg F.T., Soerensen P.S., Pfleger C.C., Rasmussen P.V., Jensen M.B., Frederiksen J.L., Bramow S., Mathiesen H.K., Schreiber K.I., Magyari M., Vukusic S., Butzkueven H., Kalincik T., University of Melbourne, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Copenhagen = Københavns Universitet (UCPH), École des Hautes Études en Santé Publique [EHESP] (EHESP), Charles University [Prague] (CU), Amiri hospital, Hospital Virgen Macarena, Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] (DEÜ), University of Catania [Italy], G.F. Ingrassia Hospital, Università degli studi 'G. d'Annunzio' Chieti-Pescara [Chieti-Pescara] (Ud'A), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Institute of Neurological Science of Bologna (IRCCS), Ondokuz Mayis University (OMU), American University of Beirut Faculty of Medicine and Medical Center (AUB), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Karadeniz Technical University (KTU), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), University of Queensland [Brisbane], Royal Brisbane & Women's Hospital [Brisbane, Australia] (RBWH), Flinders University [Adelaide, Australia], University of Newcastle [Callaghan, Australia] (UoN), Azienda Ospedaleria Universitaria di Modena, Università degli studi di Parma = University of Parma (UNIPR), University Hospital Parma, Monash University [Melbourne], The Alfred Hospital, Hasselt University (UHasselt), University of Debrecen Egyetem [Debrecen], San Giuseppe Moscati Hospital [Avellino, Italie], Westmead Hospital [Sydney], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Fondation Eugène Devic EDMUS, Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Lille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Pasteur [Nice] (CHU), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Clermont-Ferrand, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), CHI Poissy-Saint-Germain, Service de neurologie [Amiens], CHU Amiens-Picardie, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU de la Martinique [Fort de France], Service de Neurologie [CHU Limoges], CHU Limoges, CHU Henri Mondor [Créteil], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Service de Neurologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Hôpital Sud Francilien Corbeil Essonne, Centre Hospitalier de Saint-Denis [Ile-de-France], Centre Hospitalier René Dubos [Pontoise], Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Hospitalier de Versailles André Mignot (CHV), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Aarhus University Hospital, Aalborg University [Denmark] (AAU), University Hospital of Northern Sealand, Rigshospitalet [Copenhagen], Copenhagen University Hospital, The Royal Melbourne Hospital, 1140766, National Health and Medical Research Council, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Copenhagen = Københavns Universitet (KU), Università degli Studi di Bologna, University of Bari Aldo Moro (UNIBA), University of Newcastle [Australia] (UoN), University of Parma = Università degli studi di Parma [Parme, Italie], University of Debrecen, Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Ondokuz Mayis University, Centre de recherche en neurosciences de Lyon (CRNL), Physiopathologie de la Plasticité Neuronale (Neurocentre Magendie - U1215 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Internationality, Subgroup analysis, Rate ratio, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Natalizumab, Multiple Sclerosis, Relapsing-Remitting, 030225 pediatrics, Internal medicine, Secondary Prevention, Medicine, Humans, Immunologic Factors, Pharmacology (medical), Longitudinal Studies, Registries, 10. No inequality, Expanded Disability Status Scale, business.industry, Proportional hazards model, Fingolimod Hydrochloride, Multiple sclerosis, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Middle Aged, medicine.disease, Fingolimod, 3. Good health, multiple sclerosis, sex, age, natalizumab, fingolimod, big data, Psychiatry and Mental health, Cohort, Female, Neurology (clinical), business, 030217 neurology & neurosurgery, Immunosuppressive Agents, medicine.drug, Follow-Up Studies
Abstract: Introduction: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting multiple sclerosis (RRMS). Whether this association is universal for all patient groups remains to be determined. Objective: The aim of this study was to compare the relative effectiveness of natalizumab and fingolimod in RRMS subgroups defined by the baseline demographic and clinical characteristics of interest. Methods: Patients with RRMS who were given natalizumab or fingolimod were identified in a merged cohort from three international registries. Efficacy outcomes were compared across subgroups based on patients’ sex, age, disease duration, Expanded Disability Status Scale (EDSS) score, and disease and magnetic resonance imaging (MRI) activity 12 months prior to treatment initiation. Study endpoints were number of relapses (analyzed withweighted negative binomial generalized linear model) and 6-month confirmed disability worsening and improvement events (weighted Cox proportional hazards model), recorded during study therapy. Each patient was weighted using inverse probability of treatment weighting based on propensity score. Results: A total of 5148 patients (natalizumab 1989; fingolimod 3159) were included, with a mean ± standard deviation age at baseline of 38 ± 10 years, and the majority (72%) were women. The median on-treatment follow-up was 25 (quartiles 15–41) months. Natalizumab was associated with fewer relapses than fingolimod (incidence rate ratio [IRR]; 95% confidence interval [CI]) in women (0.76; 0.65–0.88); in those aged ≤38 years (0.64; 0.54–0.76); in those withdisease duration ≤7 years (0.63; 0.53–0.76); in those with EDSS score 38 years (1.34; 1.04–1.73); those with disease duration >7 years (1.33; 1.01–1.74); those with EDSS score
Published: 2021

16. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder

Author: Indrapal Singh, Jean Bastin, Patrick John McCarty, Rita Barone, Fatima Djouadi, Richard E. Frye, Mohammad A. Karim, Antonino Casabona, Amrit Ammanamanchi, Rose Shannon, Renata Rizzo, Leanna Delhey, Gestionnaire, Hal Sorbonne Université, University of Catania [Italy], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Phoenix Children's Hospital, Arkansas Children's Research Institute, and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP)
Subjects: 0301 basic medicine, medicine.medical_specialty, genetic structures, [SDV]Life Sciences [q-bio], Medicine (miscellaneous), autism spectrum disorder, Resveratrol, resveratrol, behavioral disciplines and activities, Article, Mitochondrial fatty acid, 03 medical and health sciences, Social Responsiveness Scale, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, mental disorders, energy metabolism, medicine, In patient, Fibroblast, Beta oxidation, fatty acid oxidation, business.industry, Mean age, medicine.disease, [SDV] Life Sciences [q-bio], 030104 developmental biology, medicine.anatomical_structure, Endocrinology, chemistry, acyl-carnitines, Autism spectrum disorder, Medicine, business, 030217 neurology & neurosurgery
Abstract: Patients with autism spectrum disorder (ASD) may have an increase in blood acyl-carnitine (AC) concentrations indicating a mitochondrial fatty acid β-oxidation (mtFAO) impairment. However, there are no data on systematic mtFAO analyses in ASD. We analyzed tritiated palmitate oxidation rates in fibroblasts from patients with ASD before and after resveratrol (RSV) treatment, according to methods used for the diagnosis of congenital defects in mtFAO. ASD participants (N = 10, 60%, male, mean age (SD) 7.4 (3.2) years) were divided in two age-equivalent groups based on the presence (N = 5) or absence (N = 5) of elevated blood AC levels. In addition, electron transport chain (ETC) activity in fibroblasts and muscle biopsies and clinical characteristics were compared between the ASD groups. Baseline fibroblast mtFAO was not significantly different in patients in comparison with control values. However, ASD patients with elevated AC exhibited significantly decreased mtFAO rates, muscle ETC complex II activity, and fibroblast ETC Complex II/III activity (p &lt, 0.05), compared with patients without an AC signature. RSV significantly increased the mtFAO activity in all study groups (p = 0.001). The highest mtFAO changes in response to RSV were observed in fibroblasts from patients with more severe symptoms on the Social Responsiveness Scale total (p = 0.001) and Awareness, Cognition, Communication and Motivation subscales (all p &lt, 0.01). These findings suggested recognition of an ASD patient subset characterized by an impaired mtFAO flux associated with abnormal blood AC. The study elucidated that RSV significantly increased fibroblast mtFAO irrespective of plasma AC status, and the highest changes to RSV effects on mtFAO were observed in the more severely affected patients.
Published: 2021

17. Integrating science on Xanthomonadaceae for sustainable plant disease management in Europe

Author: Vittoria Catara, Joana Costa, Ralf Koebnik, Joël F. Pothier, Marie Agnès Jacques, Emilio Stefani, Jens Boch, University of Coimbra [Portugal] (UC), Institut de Systématique, Evolution, Biodiversité (ISYEB ), Muséum national d'Histoire naturelle (MNHN)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université des Antilles (UA), Martin-Luther-University Halle-Wittenberg, Department of Life Sciences, Institut de Recherche en Horticulture et Semences (IRHS), Université d'Angers (UA)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of Catania [Italy], Plant Health Institute of Montpellier (UMR PHIM), and Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Université de Montpellier (UM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)
Subjects: Xanthomonadaceae, 0106 biological sciences, 632: Pflanzenkrankheiten, Schädlinge, Soil Science, Plant Science, 01 natural sciences, 03 medical and health sciences, Molecular Biology, ComputingMilieux_MISCELLANEOUS, Plant Diseases, 030304 developmental biology, 0303 health sciences, biology, business.industry, Disease Management, Plants, biology.organism_classification, Plant disease, Biotechnology, Europe, Editorial, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, 579: Mikrobiologie, business, Agronomy and Crop Science, 010606 plant biology & botany
Abstract: International audience
Published: 2021
Full Text: View/download PDF

18. Binge-like alcohol exposure in adolescence: behavioural, neuroendocrine and molecular evidence of abnormal neuroplasticity … and return

Author: Cesare D’Amico, Martin Kuchar, Giuseppe Tringali, Vincenzo Micale, Salvatore Feo, Gianluca Lavanco, Valentina Castelli, Anna Brancato, Giuseppe Pizzolanti, Carla Cannizzaro, Università degli studi di Palermo - University of Palermo, INSERM, Neurocentre Magendie, U1215, Physiopathologie de la Plasticité Neuronale, F-33000 Bordeaux, France, University of Catania [Italy], Università cattolica del Sacro Cuore [Roma] (Unicatt), University of Chemistry and Technology Prague (UCT Prague), ERAB: The European Foundation for Alcohol Research, Università di Catania, Brancato A., Castelli V., Lavanco G., Tringali G., Micale V., Kuchar M., D'amico C., Pizzolanti G., Feo S., Cannizzaro C., Admin, Oskar, Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), and Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt)
Subjects: Binge alcohol drinking, medicine.medical_specialty, Settore BIO/14 - FARMACOLOGIA, QH301-705.5, Medicine (miscellaneous), Nucleus accumbens, Article, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, 0302 clinical medicine, Dopamine, Dopamine receptor D2, Internal medicine, Neuroplasticity, Medicine, Cannabidiol, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Biology (General), 030304 developmental biology, Dopamine transporter, 0303 health sciences, biology, Tyrosine hydroxylase, business.industry, Dopaminergic, Adolescence, Endocrinology, biology.protein, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Adolescence, Binge alcohol drinking, Cannabidiol, Nucleus accumbens, business, 030217 neurology & neurosurgery, medicine.drug
Abstract: Binge alcohol consumption among adolescents affects the developing neural networks underpinning reward and stress processing in the nucleus accumbens (NAc). This study explores in rats the long-lasting effects of early intermittent exposure to intoxicating alcohol levels at adolescence, on: (1) the response to natural positive stimuli and inescapable stress, (2) stress-axis functionality, and (3) dopaminergic and glutamatergic neuroadaptation in the NAc. We also assess the potential effects of the non-intoxicating phytocannabinoid cannabidiol, to counteract (or reverse) the development of detrimental consequences of binge-like alcohol exposuredimensions. Our results show that adolescent binge-like alcohol exposure alters the sensitivity to positive stimuli, exerts social and novelty-triggered anxiety-like behaviour, and passive stress-coping during early and prolonged withdrawal. In addition, serum corticosterone and hypothalamic and NAc corticotropin-releasing hormone levels progressively increase during withdrawal. Besides, NAc tyrosine hydroxylase levels increase at late withdrawal, while the expression of dopamine transporter, D1 and D2 receptors xpression is dynamically altered during binge and withdrawal. Furthermore, the expression of markers of excitatory postsynaptic signaling —PSD95, Homer-1 and -2 and the activity-regulated spine-morphing proteins Arc, LIM Kinase 1 and FOXP1—increase at late withdrawal. Notably, subchronic cannabidiol, during withdrawal, attenuates social- and novelty-induced aversion and passive stress-coping and rectifies the hyper-responsive stress axis and NAc dopamine and glutamate-related neuroplasticity. Overall, the exposure to binge-like alcohol levels in adolescent rats makes the NAc, during withdrawal, a locus minoris resistentiae as a result of perturbations in neuroplasticity and in stress-axis homeostasis. Cannabidiol holds a promising potential for increasing behavioural, neuroendocrine and molecular resilience against binge-like alcohol level’s harmful effects.
Published: 2021

19. Current use of copper, mineral oils and sulphur for plant protection in organic horticultural crops across 10 European countries

Author: Katsoulas, N., Løes, A. K., Andrivon, D., Cirvilleri, G., Cara, De, Kir, M., Knebl, L., Malinska, K., Oudshoorn, F. W., Willer, H., amp, Schmutz, U., University of Thessaly [Volos] (UTH), Norwegian Centre for Organic Agriculture (NORSOK), Institut de Génétique, Environnement et Protection des Plantes (IGEPP), Université de Rennes (UR)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-INSTITUT AGRO Agrocampus Ouest, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), University of Catania [Italy], Instituto Andaluz de Investigación y Formación Agraria y Pesquera (IFAPA), Olive Research Institute, Forschungsring e.V, Częstochowa University of Technology, Danish Agriculture & Food Council, Agro Food Park, SEGES, Research Institute of Organic Agriculture - Forschungsinstitut für biologischen Landbau (FiBL), Coventry University, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Centre for Agroecology, Water and Resilience (CAWR)
Subjects: Mediterranean climate, [SDV.SA]Life Sciences [q-bio]/Agricultural sciences, plant protection, Horticultural crops, Crop health, quality, protection, Mediterranean crops, chemistry.chemical_element, Greenhouse, 010501 environmental sciences, 01 natural sciences, Tomato, Contentious inputs, Vegetables, Organic systems, Production (economics), Mediterranean crops, Greenhouse crops, Tomato, Contentious inputs, plant protection, 0105 earth and related environmental sciences, 2. Zero hunger, Sustainable development, business.industry, Agroforestry, Greenhouse crops, 04 agricultural and veterinary sciences, Copper, [SDV.BV.PEP]Life Sciences [q-bio]/Vegetal Biology/Phytopathology and phytopharmacy, chemistry, 13. Climate action, Agriculture, 040103 agronomy & agriculture, 0401 agriculture, forestry, and fisheries, Environmental science, General Agricultural and Biological Sciences, business
Abstract: International audience; The use of several plant protection inputs of mineral origin, such as copper, sulphur or mineral oils is seen as contentious by many consumers and stakeholders within the organic sector. Although the use of these inputs is legal in organic systems and also applied in non-organic agriculture, their use by organic growers raises questions for organic practice, which aspires to be free from toxic, non-renewable chemicals. Data on the current use of permitted plant protection inputs is currently scarce, especially in horticulture where chemical inputs deserve special attention since horticultural products are often readily edible. A mapping of the use of copper, sulphur and mineral oils was conducted by collecting expert knowledge across 10 European countries during May–October 2018, i.e. before the limitation of copper use to 4 kg ha−1 year−1 from February 1, 2019. Results show that copper is widely used by Mediterranean organic growers in citrus, olive, tomato and potato production. The annual limit of 6 kg ha−1 year−1 was not always respected. We also found that tomato producers apply high amounts of copper in winter crops in greenhouses. Mineral oils are applied to control scales, mites and whiteflies. Sulphur is also commonly used by organic vegetable growers, especially in greenhouses. We conclude that the high usage found in various different crops (especially Mediterranean crops) confirms the need for researching alternatives.
Published: 2020

20. TOF diagnosis of laser accelerated, high-energy protons

Author: A.G. Amico, G. Korn, Francesco Schillaci, S. Kar, Giuliana Milluzzo, R. Leanza, Giuseppina Larosa, James Green, Antonio Russo, P. Martin, Paul McKenna, F. Romano, Nicola Booth, Lorenzo Romagnani, Daniele Margarone, H. Padda, J. Pipek, Giacomo Cuttone, Giada Petringa, G.A.P. Cirrone, A. Alejo, Marco Borghesi, Domenico Doria, Valentina Scuderi, Inst Phys ASCR, ELI Beamlines Project, Laboratori Nazionali del Sud (INFN), Istituto Nazionale di Fisica Nucleare (INFN), Queen's University [Belfast] (QUB), University of Catania [Italy], Horia Hulubei Natl Inst Phys & Nucl Engn IFIN HH, ELI NP Dept, Reactorului Str 30, Magurele 077125, Romania, University of Oxford, EBG MedAustron GmbH, STFC Rutherford Appleton Laboratory (RAL), Science and Technology Facilities Council (STFC), Laboratoire pour l'utilisation des lasers intenses (LULI), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-École polytechnique (X)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and University of Oxford [Oxford]
Subjects: Nuclear and High Energy Physics, Proton, Geant4, 02 engineering and technology, 01 natural sciences, Spectral line, Ion, law.invention, Optics, law, [PHYS.PHYS.PHYS-PLASM-PH]Physics [physics]/Physics [physics]/Plasma Physics [physics.plasm-ph], 0103 physical sciences, 010306 general physics, Instrumentation, ComputingMilieux_MISCELLANEOUS, QC, Physics, ELIMED beam line, business.industry, Detector, 021001 nanoscience & nanotechnology, Laser, Multidisciplinary applications, Time of flight, Bunches, Laser-driven ions, Physics::Accelerator Physics, 0210 nano-technology, business, Beam (structure)
Abstract: Significant challenges in the detection of laser-accelerated ions result from the high flux (1010-1012 ions/pulse) and the short bunch duration which are intrinsic to laser-driven sources. The development of diagnostic techniques able to operate in real-time and on a high-rep basis is a key step towards multidisciplinary applications of such non-conventional beams. Real time diagnosis of the main beam parameters for high-energy protons accelerated by the Vulcan Petawatt (VULCAN-PW) laser system has been performed using an on line diagnostics based on the Time of Flight (TOF) technique and the use of diamond detectors. Proton energy spectra have been measured for energies exceeding 30 MeV. The results show that the TOF method employing state-of-the-art detectors is a robust real-time diagnostics, able to operate efficiently under the harsh conditions occurring with kJ-class, PW laser systems, and offering the possibility to monitor on a shot-by-shot basis the main beam parameters of high intensity proton bunches for energies up to the 100 MeV level.
Published: 2020

21. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI

Author: Akihide Konishi, Marie Claude Morice, Darren Mylotte, Sunil V. Rao, Olivier Varenne, Stuart J. Pocock, Davide Capodanno, Ernest Spitzer, Dominick J. Angiolillo, Marco Valgimigli, Takeshi Kimura, Thomas Cuisset, Hyo-Soo Kim, Andrew Farb, Deepak L. Bhatt, Norman Stockbridge, John W. Eikelboom, Roxana Mehran, Martin B. Leon, Yoshiaki Mitsutake, C. Michael Gibson, Mitchel W. Krucoff, Philip Urban, Ute Windhovel, Donald E. Cutlip, Roisin Colleran, P. F.Adrian Magee, Michael Haude, Stefan James, John Gregson, Robert A. Byrne, Pedro Eerdmans, University of Catania [Italy], Hôpital Privé Jacques Cartier [Massy], The University of Florida College of Medicine, Harvard Medical School [Boston] (HMS), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), DEKRA CONSULTING GMBH STUTTGART DEU, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), McMaster University [Hamilton, Ontario], and Technical University of Munich (TUM)
Subjects: Medtronic, and The Medicines Company, medicine.medical_treatment, Eisai, Design elements and principles, Novartis, 030204 cardiovascular system & hematology, 0302 clinical medicine, Pfizer, Chiesi, 030212 general & internal medicine, CeloNova, Amarin, Boehringer Ingelheim, Gilead, Lexicon, Bristol-Myers Squibb, Ischemix, Synaptic, Osprey Medical, AstraZeneca, Idorsia, Amgen, 3. Good health, Ethicon, Cardiology and Cardiovascular Medicine, Janssen, Bayer, medicine.medical_specialty, Ironwood, Fractyl, Forest Laboratories, Cardax, Target population, 03 medical and health sciences, Ferring Pharmaceuticals, CSL Behring, PhaseBio, medicine, high bleeding risk, Cereno Scientific, Intensive care medicine, Roche, Merck, and the Scott R. MacKenzie Foundation. Dr. Bhatt is an Advisory Board member for Cardax, business.industry, percutaneous coronary intervention, has received royalties from Elsevier, Percutaneous coronary intervention, Afimmune, Regeneron, Daiichi-Sankyo, Clinical trial, Patient population, Biosensors, Matsutani Chemical Industry, PLx Pharma, Conventional PCI, trial design, Renal Guard Solutions, Elsevier Practice Update Cardiology, Eli Lilly, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Sanofi
Abstract: International audience; Investigating the balance of risk for thrombotic and bleeding events after percutaneous coronary intervention (PCI) is especially relevant for patients at high bleeding risk (HBR). The Academic Research Consortium for HBR recently proposed a consensus definition in an effort to standardize the patient population included in HBR trials. The aim of this consensus-based document, the second initiative from the Academic Research Consortium for HBR, is to propose recommendations to guide the design of clinical trials of devices and drugs in HBR patients undergoing PCI. The authors discuss the designs of trials in HBR patients undergoing PCI and various aspects of trial design specific to HBR patients, including target populations, intervention and control groups, primary and secondary outcomes, and timing of endpoint reporting. (C) 2020 by the American College of Cardiology Foundation.
Published: 2020

22. High <scp>TG</scp> to <scp>HDL</scp> ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects

Author: Alban Redheuil, Laura D'Erasmo, Sophie Béliard, Agata Maria Rabuazzo, Roberto Scicali, Salvatore Piro, Philippe Giral, Francesco Purrello, Philippe Cluzel, Antonio Gallo, Antonino Di Pino, Eric Bruckert, Marcello Arca, University of Catania [Italy], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Sorbonne Paris Nord, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA)
Subjects: cardiovascular risk, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, prediabetes, Newly diagnosed, Type 2 diabetes, 030204 cardiovascular system & hematology, Risk profile, Gastroenterology, Prediabetic State, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Prediabetes, TG to HDL ratio, Triglycerides, coronary artery calcium, Retrospective Studies, atherosclerosis extension, type 2 diabetes, business.industry, Cholesterol, HDL, nutritional and metabolic diseases, Atherosclerosis, medicine.disease, 3. Good health, Coronary artery calcium, Cross-Sectional Studies, Diabetes Mellitus, Type 2, Lower prevalence, lipids (amino acids, peptides, and proteins), Ultrasonography, business, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; Aims We investigated the role of TG to HDL ratio (TG/HDL) on atherosclerosis extension, defined as presence of coronary artery calcium (CAC), carotid and femoral plaque, in prediabetes or newly diagnosed type 2 diabetes (T2D). Methods We performed a retrospective, cross-sectional, single centre study involving 440 prediabetes or newly diagnosed controlled T2D subjects. Participants underwent CAC analysis by computed tomography and carotid and femoral plaque evaluation by ultrasonography and were stratified in high TG/HDL (H-TG/HDL) or low TG/HDL (L-TG/HDL) group according to TG/HDL median value. We estimated atherosclerosis extension according to the number of involved vascular districts. Results CAC was higher in the H-TG/HDL group than L-TG/HDL group (29.15 [0.0-95.68] vs 0.0 [0.0-53.97] AU,P < .01) and CAC > 0 was more prevalent in the H-TG/HDL group than L-TG/HDL group (64.5% vs 45%,P < .001). Femoral atherosclerosis was higher in the H-TG/HDL group than L-TG/HDL group (57.3% vs 43.6%,P < .01). H-TG/HDL group exhibited a lower prevalence of subjects with 0-TWP compared to L-TG/HDL group (21.8% vs 38.6%,P < .01) and higher percentages of subjects with 2-TWP or 3-TWP than L-TG/HDL group (for 2-TWP 29.5% vs 21.5%,P < .05; for 3-TWP 32.7% vs 20.9%,P < .01). Multiple logistic regression analysis showed that a H-TG/HDL was inversely associated to 0-TWP (P < .05) and positively associated with 2-TWP (P < .05) and 3-TWP (P < .01). Conclusions Our data suggest that TG/HDL is a marker of increased atherosclerotic extension in prediabetes and newly diagnosed T2D and may be useful to identify subjects with a higher cardiovascular risk profile.
Published: 2020

23. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

Author: Hideyuki Kawashima, Scot Garg, Chao Gao, Hironori Hara, Nick Curzen, Dominika Klimczak-Tomaniak, Christian W. Hamm, Dominick J. Angiolillo, Marco Valgimigli, Pascal Vranckx, Richard Anderson, Norihiro Kogame, Davide Capodanno, Masafumi Ono, Rutao Wang, Ply Chichareon, Rodrigo Modolo, Michael Haude, Mariusz Tomaniak, Yoshinobu Onuma, Janusz Kochman, Robert F. Storey, Tessa Rademaker-Havinga, Tommaso Gori, Stephan Windecker, Gilles Montalescot, Patrick W. Serruys, Kuniaki Takahashi, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Medical University of Warsaw - Poland, Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), University of Campinas [Campinas] (UNICAMP), Xijing Hospital, Radboud university [Nijmegen], University Medical Center [Mainz], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Catania [Italy], University of Sheffield [Sheffield], Bern University Hospital [Berne] (Inselspital), National University of Ireland [Galway] (NUI Galway), Imperial College London, National Heart and Lung Institute [London] (NHLI), Royal Brompton and Harefield NHS Foundation Trust-Imperial College London, University of Wales, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, Graduate School, Cardiology, ACS - Heart failure & arrhythmias, University of Zurich, and Serruys, Patrick W
Subjects: Male, Acute coronary syndrome, medicine.medical_specialty, Ticagrelor, Impaired renal function, medicine.medical_treatment, Aspirin-free antiplatelet strategies, [SDV]Life Sciences [q-bio], 610 Medicine & health, Coronary Artery Disease, 030204 cardiovascular system & hematology, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, Percutaneous coronary intervention, Coronary artery disease, 03 medical and health sciences, Chronic kidney disease, DAPT, 0302 clinical medicine, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Myocardial infarction, Renal Insufficiency, Acute Coronary Syndrome, Aged, business.industry, Dual Anti-Platelet Therapy, Hazard ratio, Drug-Eluting Stents, General Medicine, Middle Aged, medicine.disease, 3. Good health, Treatment Outcome, Conventional PCI, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors, medicine.drug, Glomerular Filtration Rate
Abstract: Background: Impaired renal function (IRF) is associated with increased risks of both ischemic and bleeding events. Ticagrelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in those with versus without IRF. Methods: A pre-specified sub-analysis of the randomized GLOBAL LEADERS trial (n = 15,991) comparing the experimental strategy of 23-month ticagrelor monotherapy (after 1-month ticagrelor and aspirin dual anti-platelet therapy [DAPT]) with 12-month DAPT followed by 12-month aspirin after percutaneous coronary intervention (PCI) in ACS and stable coronary artery disease (CAD) patients stratified according to IRF (glomerular filtration rate < 60 ml/min/1.73 m 2). Results: At 2 years, patients with IRF (n = 2171) had a higher rate of the primary endpoint (all-cause mortality or centrally adjudicated, new Q-wave myocardial infarction [MI](hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.35–1.98, p adj = 0.001), all-cause death, site-reported MI, all revascularization and BARC 3 or 5 type bleeding, compared with patients without IRF. Among patients with IRF, there were similar rates of the primary endpoint (HR 0.82, 95% CI 0.61–1.11, p = 0.192, p int = 0.680) and BARC 3 or 5 type bleeding (HR 1.10, 95% CI 0.71–1.71, p = 0.656, p int = 0.506) in the experimental versus the reference group. No significant interactions were seen between IRF and treatment effect for any of the secondary outcome variables. Among ACS patients with IRF, there were no between-group differences in the rates of the primary endpoint or BARC 3 or 5 type bleeding; however, the rates of the patient-oriented composite endpoint (POCE) of all-cause death, any stroke, MI, or revascularization (p int = 0.028) and net adverse clinical events (POCE and BARC 3 or 5 type bleeding) (p int = 0.045), were lower in the experimental versus the reference group. No treatment effects were found in stable CAD patients categorized according to presence of IRF. Conclusions: IRF negatively impacted long-term prognosis after PCI. There were no differential treatment effects found with regard to all-cause death or new Q-wave MI after PCI in patients with IRF treated with ticagrelor monotherapy. Clinical trial registration: The trial has been registered with ClinicalTrials.gov, number NCT01813435. Graphic abstract: [Figure not available: see fulltext.].
Published: 2020

24. The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN‐TAVI) registry

Author: Nicholas Dumonteil, Piera Capranzaro, Samantha Sartori, Bimmer E. Claessen, Roxana Mehran, Daniela Trabattoni, Davide Cao, Thierry Lefèvre, Didier Tchetche, Usman Baber, Alaide Chieffo, Anna Sonia Petronio, Rishi Chandiramani, Dhrubajyoti Bandyopadhyay, Chiara Fraccaro, Annapoorna Kini, Christoph Naber, Patrizia Presbitero, Nicolas M. Van Mieghem, Jaya Chandrasekhar, Marie Claude Morice, Ghada W. Mikhail, Gennaro Sardella, Julinda Mehilli, Icahn School of Medicine at Mount Sinai [New York] (MSSM), Clinique Pasteur [Toulouse], Ludwig-Maximilians-Universität München (LMU), Hôpital Privé Jacques Cartier [Massy], Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), University of Catania [Italy], Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Erasmus University Medical Center [Rotterdam] (Erasmus MC), Hôpital de Rangueil, CHU Toulouse [Toulouse], Universita degli Studi di Padova, Centro Cardiologico Monzino [Milano], Dpt di Scienze Cliniche e di Comunità [Milano] (DISCCO), Università degli Studi di Milano [Milano] (UNIMI)-Università degli Studi di Milano [Milano] (UNIMI)-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Imperial College London, San Raffaele Scientific Institute, Vita-Salute San Raffaele University and Center for Translational Genomics and Bioinformatics, and Cardiology
Subjects: medicine.medical_treatment, [SDV]Life Sciences [q-bio], aortic valve stenosis, 030204 cardiovascular system & hematology, urologic and male genital diseases, time factors, renal insufficiency, 0302 clinical medicine, Valve replacement, 80 and over, risk factors, 030212 general & internal medicine, Myocardial infarction, humans, Aged, 80 and over, glomerular filtration rate, Hazard ratio, risk assessment, General Medicine, aortic valve, female genital diseases and pregnancy complications, 3. Good health, chronic, aged, retrospective studies, female, Cardiology, transcatheter aortic valve replacement, Hemodialysis, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, kidney, Renal function, aortic stenosis, chronic kidney disease, WIN-TAVI registry, aged, 80 and over, registries, severity of illness index, sex factors, treatment outcome, renal insufficiency, chronic, 03 medical and health sciences, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Renal Insufficiency, Chronic, business.industry, Percutaneous coronary intervention, EuroSCORE, medicine.disease, business, Kidney disease
Abstract: International audience; Background: The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown.Methods: Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1-year follow-up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m2 ); (b) mild CKD (stage 3a CKD: eGFR = 45-59 ml/min/1.73 m2 ); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR
Published: 2020

25. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease

Author: Manesh R. Patel, Jeffrey I. Weitz, Davide Capodanno, Uwe Zeymer, Tobias Geisler, P. Gabriel Steg, Pascal Vranckx, Stefan James, Renato D. Lopes, Keith A.A. Fox, Gilles Montalescot, C. Michael Gibson, Robert F. Storey, John W. Eikelboom, Robert C. Welsh, José Ramón González-Juanatey, Dominick J. Angiolillo, Roxana Mehran, Deepak L. Bhatt, University of Catania [Italy], Harvard Medical School [Boston] (HMS), McMaster University [Hamilton, Ontario], University of Edinburgh, Universitätsklinikum Tübingen - University Hospital of Tübingen, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen, Beth Israel Deaconess Medical Center [Boston] (BIDMC), Uppsala University, Duke University [Durham], Icahn School of Medicine at Mount Sinai [New York] (MSSM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, University of Sheffield [Sheffield], Hasselt University (UHasselt), and University of Alberta
Subjects: 0301 basic medicine, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Ischemia, Disease, 030204 cardiovascular system & hematology, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Thrombin, Drug Therapy, Fibrinolytic Agents, Antithrombotic, Medicine, Humans, Intensive care medicine, Anticoagulant drug, business.industry, Anticoagulants, Thrombosis, medicine.disease, 3. Good health, Residual risk, 030104 developmental biology, Cardiovascular Diseases, Combination, Drug Therapy, Combination, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors, medicine.drug, Factor Xa Inhibitors
Abstract: International audience; Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleeding. The advent of non-vitamin K antagonist oral anticoagulants, which attenuate fibrin formation by selective inhibition of factor Xa or thrombin, has renewed the interest in dual-pathway inhibition strategies that combine an antiplatelet agent with an anticoagulant drug. In this Review, we highlight the emerging pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with different manifestations of cardiovascular disease, such as coronary artery disease, cerebrovascular disease and peripheral artery disease.
Published: 2020

26. COVID-19 Therapeutic and Prevention

Author: Didier Raoult, Jean-Marc Rolain, Po-Ren Hsueh, Stefania Stefani, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, National Taiwan University [Taiwan] (NTU), Department of Biomedical and Biotechnological Sciences [Catania, Italy], University of Catania [Italy], and Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille)
Subjects: Microbiology (medical), 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, 03 medical and health sciences, Betacoronavirus, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, Viral therapy, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Pharmacology (medical), Pandemics, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, biology, 030306 microbiology, business.industry, SARS-CoV-2, COVID-19, General Medicine, biology.organism_classification, medicine.disease, Virology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Pneumonia, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, business, Coronavirus Infections
Abstract: International audience
Published: 2020
Full Text: View/download PDF

27. Resource allocation for edge computing with multiple tenant configurations

Author: Antonella Di Stefano, Andrea Araldo, Alessandro Di Stefano, Département Réseaux et Services de Télécommunications (RST), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), Méthodes et modèles pour les réseaux (METHODES-SAMOVAR), Services répartis, Architectures, MOdélisation, Validation, Administration des Réseaux (SAMOVAR), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP)-Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), Institut Polytechnique de Paris (IP Paris), and University of Catania [Italy]
Subjects: Container systems, Service (systems architecture), Computer science, Distributed computing, Network management, Cloud computing, 02 engineering and technology, Network virtualization, Base station, n-tier architectures, [INFO.INFO-NI]Computer Science [cs]/Networking and Internet Architecture [cs.NI], Resource (project management), 020204 information systems, 0202 electrical engineering, electronic engineering, information engineering, Networks → Cloud computing, Resource allocation, Edge computing, business.industry, ACM: C.: Computer Systems Organization/C.2: COMPUTER-COMMUNICATION NETWORKS/C.2.3: Network Operations/C.2.3.0: Network management, 020207 software engineering, Service provider, Cloud Computing, Elasticity (cloud computing), Programmable networks, Computer systems organization → Cloud computing, Enhanced Data Rates for GSM Evolution, business, Network optimization
Abstract: International audience; Edge Computing (EC) consists in deploying computational resources, e.g., memory, CPUs, at the Edge of the network, e.g., base stations, access points, and run there a part of the computation currently running on the Cloud. This approach promises to reduce latency, inter-domain traffic and enhance user experience. Since resources at the Edge are scarce, resource allocation is crucial for EC. While most of the studies assume users interact directly with the Edge submitting a sequence of tasks, we instead consider that users will interact with different Service Providers (SPs), as they currently do in the Web. We therefore consider the case of a Network Operator (NO) that owns the resources at the Edge and must decide how much resource to allocate to the different tenants (SPs). We propose MORA, a polynomial time strategy which allows the NO to maximize its utility, which can be inter-domain traffic savings, improved users' QoE or other metrics of interest. The core of MORA is that (i) it exploits service elasticity, i.e., the fact that services can adapt to the resources allocated by the NO and rely on a remote Cloud for the excess of computation, (ii) it is suitable for micro-services architecture, which decomposes a single service in a set of components, which MORA places in the different computational nodes of the Edge and (iii) it copes with multi-dimensional resources, e.g., memory and CPUs. After analyzing the properties of the algorithm, we show numerically that it performs close to the optimum. To guarantee reproducibility, the numerical evaluation is performed on publicly available traces from Google and Alibaba clusters and in synthetic scenarios and our code is open source.
Published: 2020

28. The role of hypoxia and SRC tyrosine kinase in glioblastoma invasiveness and radioresistance

Author: Gaetano Magro, Federica M. Spitale, Rosario Gulino, Lucia Salvatorelli, Giacomo Cuttone, Filippo Torrisi, Rosalba Parenti, Luigi Minafra, Giorgio Ivan Russo, Nunzio Vicario, Francesco Paolo Cammarata, Samuel Valable, Department of Biomedical and Biotechnological Sciences [Catania, Italy], University of Catania [Italy], Institute of Molecular Bioimaging and Physiology, National Research Council, Università degli studi di Catania [Catania], Istituto Nazionale di Fisica Nucleare, Sezione di Catania (INFN), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Laboratori Nazionali del Sud (LNS), Istituto Nazionale di Fisica Nucleare (INFN), and Università degli studi di Catania = University of Catania (Unict)
Subjects: 0301 basic medicine, Cancer Research, medicine.medical_treatment, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Brain tumor, [SDV.CAN]Life Sciences [q-bio]/Cancer, Review, lcsh:RC254-282, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, SRC tyrosine kinase, Radioresistance, medicine, business.industry, hypoxia, Hypoxia (medical), lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, invasion, targeted therapy, Radiation therapy, radioresistance, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, medicine.symptom, business, Glioblastoma, Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src
Abstract: Simple Summary The biological pathways underlying glioblastoma malignancy and radioresistance are still unclear. In this review, we describe the role of the hypoxic microenvironment and SRC proto-oncogene non-receptor tyrosine kinase in the activation of radioresistance and invasion pathways of glioblastoma. We also highlight the hypoxia- and ionizing radiation-induced infiltration, providing updated evidences on the involvement of SRC in these processes. Optimizing radiotherapy and identifying druggable molecular players are crucial steps to improve current glioblastoma therapeutic strategies. Abstract Advances in functional imaging are supporting neurosurgery and radiotherapy for glioblastoma, which still remains the most aggressive brain tumor with poor prognosis. The typical infiltration pattern of glioblastoma, which impedes a complete surgical resection, is coupled with a high rate of invasiveness and radioresistance, thus further limiting efficient therapy, leading to inevitable and fatal recurrences. Hypoxia is of crucial importance in gliomagenesis and, besides reducing radiotherapy efficacy, also induces cellular and molecular mediators that foster proliferation and invasion. In this review, we aimed at analyzing the biological mechanism of glioblastoma invasiveness and radioresistance in hypoxic niches of glioblastoma. We also discussed the link between hypoxia and radiation-induced radioresistance with activation of SRC proto-oncogene non-receptor tyrosine kinase, prospecting potential strategies to overcome the current limitation in glioblastoma treatment.
Published: 2020

29. Composing Communicating Systems, Synchronously

Author: Ivan Lanese, Franco Barbanera, Emilio Tuosto, University of Catania [Italy], Foundations of Component-based Ubiquitous Systems (FOCUS), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Dipartimento di Informatica - Scienza e Ingegneria [Bologna] (DISI), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Alma Mater Studiorum University of Bologna (UNIBO), Gran Sasso Science Institute (GSSI), Istituto Nazionale di Fisica Nucleare (INFN), University of Leicester, European Project: 778233,H2020-EU.1.3.3. - Stimulating innovation by means of cross-fertilisation of knowledge ,778233,BEHAPI(2018), T. Margaria, B. Steffen, Barbanera F., Lanese I., and Tuosto E.
Subjects: 050101 languages & linguistics, [INFO.INFO-PL]Computer Science [cs]/Programming Languages [cs.PL], Computer science, business.industry, Forwarder, 05 social sciences, Message passing, Composizionalita', message passing, deadlock, 02 engineering and technology, Deadlock, [INFO.INFO-FL]Computer Science [cs]/Formal Languages and Automata Theory [cs.FL], Asynchronous communication, 0202 electrical engineering, electronic engineering, information engineering, 020201 artificial intelligence & image processing, 0501 psychology and cognitive sciences, Everyday life, business, Composition (language), Computer network
Abstract: Conference moved to 2021 due to covid-19; International audience; Communicating systems are nowadays part of everyday life, yet programming and analysing them is difficult. One of the many reasons for this difficulty is their size, hence compositional approaches are a need. We discuss how to ensure relevant communication properties such as deadlock freedom in a compositional way. The idea is that communicating systems can be composed by taking two of their participants and transforming them into coupled forwarders connecting the two systems. It has been shown that, for asynchronous communications, if the participants are "compatible" then composition satisfies relevant communication properties provided that the single systems satisfy them. We show that such a result changes considerably for synchronous communications. We also discuss a different form of composition, where a unique forwarder is used.
Published: 2020

30. Primary results from the STARLINER study of disease behaviour in suspected ILD

Author: Frank Gilberg, Syed Anees, Claudia Valenzuela, Carlo Vancheri, Michael T. Henry, Monica Bengus, Elisabeth Bendstrup, Klaus-Uwe Kirchgaessler, Mirela Mirt, Alessandro G. Fois, Marlies S. Wijsenbeek, Stéphane Jouneau, Catharina C. Moor, Onofre Moran, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Aarhus University Hospital, Universidad Autonoma de Madrid (UAM), University College Cork (UCC), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Università degli Studi di Sassari [Sassari] (UNISS), Queen's University [Kingston, Canada], University of Windsor [Ca], F. Hoffmann-La Roche [Basel], University of Catania [Italy], Universidad Autónoma de Madrid (UAM), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Università degli Studi di Sassari = University of Sassari [Sassari] (UNISS)
Subjects: Spirometry, medicine.medical_specialty, Primary (chemistry), medicine.diagnostic_test, business.industry, [SDV]Life Sciences [q-bio], Idiopathic pulmonary fibrosis, Disease behaviour, medicine.disease, Internal medicine, Diagnosis, medicine, business, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2020

31. Can contamination by major systemic insecticides affect the voracity of the harlequin ladybird?

Author: Antonio Biondi, Yanhui Lu, Michele Ricupero, Roberto Puglisi, Changchun Dai, Nicolas Desneux, Lucia Zappalà, University of Catania [Italy], Chinese Academy of Agricultural Sciences (CAAS), Institut Sophia Agrobiotech (ISA), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Côte d'Azur (UCA), University of Catania (Project Emergent Pests and Pathogens and Relative Sustainable Strategies) 5A722192113, European Project: 611810, and Université Nice Sophia Antipolis (... - 2019) (UNS)
Subjects: Insecticides, Pyridines, [SDV]Life Sciences [q-bio], Health, Toxicology and Mutagenesis, 0208 environmental biotechnology, 02 engineering and technology, 010501 environmental sciences, 01 natural sciences, Functional response, Toxicology, chemistry.chemical_compound, Neonicotinoids, Aphis gossypii, Neonicotinoid, Sulfoxaflor, Biocontrol Cotton aphid Functional response Integrated pest management Neonicotinoid Sulfoximine, Aphid, biology, food and beverages, Integrated pest management, General Medicine, Nitro Compounds, Pollution, Coleoptera, [SDE]Environmental Sciences, Thiamethoxam, Environmental Engineering, Lethal Dose 50, Imidacloprid, Environmental Chemistry, Animals, Sulfoximine, 0105 earth and related environmental sciences, Sulfur Compounds, business.industry, Public Health, Environmental and Occupational Health, Pest control, Biocontrol, General Chemistry, biology.organism_classification, Harmonia axyridis, 020801 environmental engineering, Cotton aphid, chemistry, 13. Climate action, Aphids, Predatory Behavior, business
Abstract: International audience; Systemic neurotoxic insecticides are widely used to control aphid pests worldwide and their potential non-target effects on aphid predators are often unknown. Behavioral responses linked to biological control services are crucial when assessing the compatibility of chemicals with biocontrol organisms. This is particularly relevant for insecticides at low and sublethal concentrations. We studied the acute toxicity and the sublethal effect on the voracity of the generalist predator Harmonia axyridis (Coleoptera: Coccinellidae) caused by the exposure to three systemic insecticides routinely used against aphids. The tested insecticide concentrations were the Lethal Concentration 50% (LC50), 20% (LC20) and 1% (LC1) estimated for the target pest Aphis gossypii (Hemiptera: Aphididae) in a companion study. The survival and the voracity differed among the tested chemicals and concentrations, but only thiamethoxam at LC50 caused a significant predator mortality, and individuals that survived showed a reduced predation rate. The predators showed a density independent functional response after the exposure to most of the insecticide-concentration combinations, while an inverse density dependence of the prey consumption rate was observed for coccinellids exposed to sulfoxaflor and thiamethoxam at their lowest tested concentration. The estimated parameters, i.e., the attack rate and the prey handling time, were affected at higher concentrations by both imidacloprid and sulfoxaflor. These findings stress the importance of carefully evaluating side effects of insecticides at very low concentrations on beneficial arthropods in the risk assessment schemes for sustainable pest control programmes.
Published: 2020

32. Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes

Author: Javier Escaned, Nicola Ryan, Daniela Trabattoni, Davide Capodanno, Giuseppe Venuti, Iván J. Núñez-Gil, Bernardo Cortese, Gaetano M. De Ferrari, Roberto Garbo, Ovidio De Filippo, Claudio Moretti, Guglielmo Gallone, Francesco Romeo, Carlo Di Mario, Ferdinando Varbella, Saverio Muscoli, Wojciech Wojakowski, Zenon Huczek, Filippo Figini, Maurizio D'Amico, Mario Iannaccone, Giorgio Quadri, Imad Sheiban, Gérard Helft, Grzegorz Smolka, Giacomo Boccuzzi, Alessio Mattesini, Cristina Rolfo, Yoichi Imori, Andrea Montabone, Wojciech Wańha, Radosław Parma, Andrea Rognoni, Umberto Morbiducci, Francesca De Lio, Diego Gallo, Federico Conrotto, Lorenzo Zaccaro, Leonardo De Luca, Fabrizio D'Ascenzo, Satoru Mitomo, Alaide Chieffo, Mauro Pennone, Gestionnaire, Hal Sorbonne Université, Civil Hospital SS. Annunziata [Savigliano, Italy] (CH2SA), Università degli studi di Torino = University of Turin (UNITO), IRCCS Ospedale San Raffaele [Milan, Italy], Medical University of Silesia (SUM), Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Università degli Studi di Roma Tor Vergata [Roma], University of Catania [Italy], Ospedale San Giovanni Bosco [Turin, Italy] (OSGB), Ospedale di Rivoli [Rivoli, Italy] (OR), University Hospital 'Maggiore della Carità' [Novara, Italy], Institut de cardiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Politecnico di Torino = Polytechnic of Turin (Polito), Ospedale San Giovanni Evangelista [Rome, Italy] (OSGE), Clinica Pederzoli [Peschiera del Garda, Italy] (CP), Nippon Medical School [Tokyo, Japon], Careggi University Hospital [Florence, Italie], Medical University of Warsaw - Poland, ASST Fatebenefratelli-Sacco [Milan, Italy], Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Azienda Ospedalerio - Universitaria Città della Salute e della Scienza di Torino = University Hospital Città della Salute e della Scienza di Torino, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Target lesion, Male, medicine.medical_specialty, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Coronary Artery Disease, 030204 cardiovascular system & hematology, Prosthesis Design, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Left coronary artery, Percutaneous Coronary Intervention, Risk Factors, medicine.artery, Internal medicine, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Zotarolimus, cardiovascular diseases, 030212 general & internal medicine, Registries, Aged, Retrospective Studies, Everolimus, business.industry, Hazard ratio, Stent, Percutaneous coronary intervention, Drug-Eluting Stents, General Medicine, Middle Aged, equipment and supplies, [SDV] Life Sciences [q-bio], Europe, surgical procedures, operative, Treatment Outcome, Conventional PCI, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: International audience; Objectives: To evaluate the independent clinical impact of stent structural features in a large cohort of patients undergoing unprotected left main (ULM) or coronary bifurcation percutaneous coronary intervention (PCI) with a range of very thin strut stents.Background: Clinical impact of structural features of contemporary stents remains to be defined.Methods: All consecutive patients enrolled in the veRy thin stents for patients with left mAIn or bifurcatioN in real life (RAIN) registry were included. The following stent structural features were studied: antiproliferative drugs (everolimus vs. sirolimus vs. zotarolimus), strut material (platinum-chromium vs. cobalt-chromium), polymer (bioresorbable vs. durable), number of crowns (
Published: 2020

33. Co-management of fisheries through a negotiation lens: The case of prud’homies

Author: Iuri Peri, Yazdan Soltanpour, Leïla Temri, Marchés, Organisations, Institutions et Stratégies d'Acteurs (UMR MOISA), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), University of Catania, University of Catania [Italy], Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut National de la Recherche Agronomique (INRA)-Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro), and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)
Subjects: 0106 biological sciences, Marine conservation, marine fisheries, Maximum sustainable yield, media_common.quotation_subject, Geography, Planning and Development, Fishing, Management, Monitoring, Policy and Law, Development, Aquatic Science, Fish stock, 01 natural sciences, media_common.cataloged_instance, participation, 14. Life underwater, European union, local fihing community, Water Science and Technology, media_common, gouvernance, Interactive governance, Local fishing community, Participation, Voice, Corporate governance, voice, 04 agricultural and veterinary sciences, interactive governance, 010601 ecology, Fishery, Negotiation, Incentive, governance, 040102 fisheries, 0401 agriculture, forestry, and fisheries, voix, [SHS.GESTION]Humanities and Social Sciences/Business administration, Business, pêche maritime
Abstract: International audience; While the European Union’s fishing policy is mainly based on maximum sustainable yield, at the local fishing community level, fishers’ main incentive to sustain fish stocks appears to be maintenance of social relationships. Divergence of the stakeholders’ objectives on the management of marine resources creates conflicts of interest that can be overcome through a process of negotiation. The formulation of the solution is embedded in the perspective of the stakeholders. In this paper we analyze the negotiation mechanisms between the French Mediterranean local fishing communities and the European Union common fishery policy. Inspired by interactive governance theory, the performance of Prud’homies, a local governance entity in the French Mediterranean, has been analyzed through their capacity to cooperate and represent the fishers’ voice in formal institutes. We are witnessing a declining representation of this local institute among the official decision-makers of the marine resource governance.
Published: 2020

34. A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease

Author: Harald Hampel, Filippo Caraci, A. Claudio Cuello, Giuseppe Caruso, Robert Nisticò, Massimo Corbo, Filippo Baldacci, Nicola Toschi, Francesco Garaci, Patrizia A. Chiesa, Steven R. Verdooner, Leyla Akman-Anderson, Félix Hernández, Jesús Ávila, Enzo Emanuele, Pedro L. Valenzuela, Alejandro Lucía, Mark Watling, Bruno P. Imbimbo, Andrea Vergallo, Simone Lista, Gestionnaire, Hal Sorbonne Université, Alzheimer Precision Medicine [CHU Pitié-Salpétriêre] (GRC 21 APM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Catania [Italy], Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), McGill University = Université McGill [Montréal, Canada], University of Oxford, Università degli Studi di Roma Tor Vergata [Roma], European Brain Research Institute [Rome, Italy] (EBRI), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de la Mémoire et de la Maladie d'Alzheimer [CHU Pitié-Salpétriêre] (IM2A), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], University of Pisa - Università di Pisa, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Harvard Medical School [Boston] (HMS), NeuroVision Imaging, Centro de Biología Molecular Severo Ochoa [Madrid] (CBMSO), Universidad Autónoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC), Universidad de Alcalá - University of Alcalá (UAH), Universidad Europea de Madrid = European University of Madrid (UEM), Hospital Universitario 12 de Octubre [Madrid], Alzheimer Precision Medicine [CHU Pitié-Salpétriêre] (GRC 21 AMP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Oxford [Oxford], Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] (IM2A), Sorbonne Université (SU), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Massachusetts General Hospital [Boston]-Harvard Medical School [Boston] (HMS), Universidad Autonoma de Madrid (UAM)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Universidad Europea de Madrid, Sorbonne Université, Fondation pour la Recherche sur Alzheimer, and AXA Research Fund
Subjects: 0301 basic medicine, Proteomics, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Enfermedad del sistema nervioso, microglia, Review, Genética humana, neuroinflammation, Tratamiento médico, 0302 clinical medicine, Enfermedad de Alzheimer, Medicine, Immunology and Allergy, Cell Self Renewal, Terapeútica, Antiinflammatory therapy, Microglia, Neurodegeneration, Settore BIO/14, systems biology, Alzheimer's disease, 3. Good health, medicine.anatomical_structure, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Neurogenic Inflammation, Alzheimer’s disease, Signal Transduction, lcsh:Immunologic diseases. Allergy, [SDV.IMM] Life Sciences [q-bio]/Immunology, Systems biology, precision medicine, Immunology, anti-inflammatory therapy, biomarkers, neuroinflammatory pathways, Proinflammatory cytokine, 03 medical and health sciences, Alzheimer Disease, Animals, Humans, Neuroinflammation, business.industry, TREM2, Mechanism (biology), [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, medicine.disease, Precision medicine, Lipid Metabolism, 030104 developmental biology, business, lcsh:RC581-607, Neuroscience, 030215 immunology, Genome-Wide Association Study
Abstract: Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and represents one of the earliest pathomechanistic alterations throughout the AD continuum. Large-scale genome-wide association studies point out several genetic variants—TREM2, CD33, PILRA, CR1, MS4A, CLU, ABCA7, EPHA1, and HLA-DRB5-HLA-DRB1—potentially linked to neuroinflammation. Most of these genes are involved in proinflammatory intracellular signaling, cytokines/interleukins/cell turnover, synaptic activity, lipid metabolism, and vesicle trafficking. Proteomic studies indicate that a plethora of interconnected aberrant molecular pathways, set off and perpetuated by TNF-α, TGF-β, IL-1β, and the receptor protein TREM2, are involved in neuroinflammation. Microglia and astrocytes are key cellular drivers and regulators of neuroinflammation. Under physiological conditions, they are important for neurotransmission and synaptic homeostasis. In AD, there is a turning point throughout its pathophysiological evolution where glial cells sustain an overexpressed inflammatory response that synergizes with amyloid-β and tau accumulation, and drives synaptotoxicity and neurodegeneration in a self-reinforcing manner. Despite a strong therapeutic rationale, previous clinical trials investigating compounds with anti-inflammatory properties, including non-steroidal anti-inflammatory drugs (NSAIDs), did not achieve primary efficacy endpoints. It is conceivable that study design issues, including the lack of diagnostic accuracy and biomarkers for target population identification and proof of mechanism, may partially explain the negative outcomes. However, a recent meta-analysis indicates a potential biological effect of NSAIDs. In this regard, candidate fluid biomarkers of neuroinflammation are under analytical/clinical validation, i.e., TREM2, IL-1β, MCP-1, IL-6, TNF-α receptor complexes, TGF-β, and YKL-40. PET radio-ligands are investigated to accomplish in vivo and longitudinal regional exploration of neuroinflammation. Biomarkers tracking different molecular pathways (body fluid matrixes) along with brain neuroinflammatory endophenotypes (neuroimaging markers), can untangle temporal–spatial dynamics between neuroinflammation and other AD pathophysiological mechanisms. Robust biomarker–drug codevelopment pipelines are expected to enrich large-scale clinical trials testing new-generation compounds active, directly or indirectly, on neuroinflammatory targets and displaying putative disease-modifying effects: novel NSAIDs, AL002 (anti-TREM2 antibody), anti-Aβ protofibrils (BAN2401), and AL003 (anti-CD33 antibody). As a next step, taking advantage of breakthrough and multimodal techniques coupled with a systems biology approach is the path to pursue for developing individualized therapeutic strategies targeting neuroinflammation under the framework of precision medicine., Sorbonne University Foundation and sponsored by la Fondation pour la Recherche sur Alzheimer. HH is an employee of Eisai Inc. During his previous work (until April 2019), he was supported by the AXA Research Fund, the Fondation partenariale Sorbonne Université and the Fondation pour la Recherche sur Alzheimer, Paris, France
Published: 2020

35. Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy – an E-AHPBA multi-center study

Author: Rystedt, J.M.L., Kleeff, J., Salvia, R., Besselink, M.G., Prasad, R., Lesurtel, M., Sturesson, C., Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B.A., Boonstra, E.A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., Gelder, A. de, Rose, A.M. de, Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T.K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K.H., Hartman, V., Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, B., Jonas, E., K.A., Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V., Lucidi, V., Mabrut, J.Y., Mansson, C., Mieog, S., Mirza, D.F., Oldhafer, K.J., Omoshoro-Jones, J.A.O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R.J., Poves, I., Calvo, M.P., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A.K., Smith, M.D., Silva, D.S., Sparrelid, E., Stattner, S., Stavrou, G.A., Straka, M., Stromberg, C., Sutcliffe, R.P., Szijarto, A., Taflin, H., Trotovsek, B., Gulik, T. van, Wallach, N., Zieniewicz, K., European-African HepatoPancreato, Skane University Hospital [Lund], Fachbereich Physik [Halle-Saale], Martin-Luther-Universität Halle Wittenberg (MLU), Azienda Ospedaliera Universitaria Integrata of Verona, University of Amsterdam [Amsterdam] (UvA), St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Karolinska University Hospital [Stockholm], University of Southampton, Policlinico di Monza, Partenaires INRAE, Universita 'La Sapienza' Roma (Istituto CNR), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Catholic University, Rome, Italy, Complexo Hospitalario Universitario de Vigo, Ghent University Hospital, Linköping University (LIU), Universiteit Leiden [Leiden], University Medical Center Groningen [Groningen] (UMCG), Universiteit Antwerpen [Antwerpen], Universidad de Murcia, J. G. Mendel Cancer Center Novy Jicin, Universidad de Salamanca, Hospital Dr Josep Trueta de Girona, Izmir University, TURKEY, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto, University of Ljubljana, University of Warsaw (UW), İZMİR EGE University Medical Faculty Hospital, Univeristà di Genova, Semmelweis University of Medicine [Budapest], University of Dublin, Universidad de Deusto [Bilbao] (DEUSTO), Universidad de Deusto (DEUSTO), Hospital Universitario Cruces = Cruces University Hospital, Hadassah Hebrew University Hospital, The Hebrew University of Jerusalem (HUJ), Catholic University of Rome, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Queens Elizabeth Hospital [Birmingham], University of Iceland [Reykjavik], Community Hospital of horn, Umeå University, University Hospital Motol [Prague], Uppsala Universitet [Uppsala], University of Cape Town, Hadassah Hebrew University Medical Center [Jerusalem], Community Hospital Horn, CHU Amiens-Picardie, Vrije Universiteit Brussel (VUB), Université de Lyon, Asklepios Klinik Barmbek, University of Johannesburg (UJ), Vall d'Hebron University Hospital [Barcelona], Facultad de Medicina [Zaragoza], University of Zaragoza - Universidad de Zaragoza [Zaragoza], Cerrahpasa Medical Faculty, University of Catania [Italy], IMIM-Hospital del Mar, Generalitat de Catalunya, Innsbruck Medical University [Austria] (IMU), Unité Expérimentale Recherches Intégrées - Gotheron (UERI), Institut National de la Recherche Agronomique (INRA), University of Pristina-Kosovo, Peja/Pec Hospital, Sahlgrenska Academy at University of Gothenburg [Göteborg], Universidad de Málaga [Málaga] = University of Málaga [Málaga], University Hospital Düsseldorf, Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), Manchester Royal Infirmary, University of Manchester [Manchester], Chris Hani Baragwanath Hospital, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), European-African HepatoPancreato, Ege Üniversitesi, Groningen Institute for Organ Transplantation (GIOT), Surgery, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and Quality of Life, and AGEM - Endocrinology, metabolism and nutrition
Subjects: INTRAOPERATIVE CHOLANGIOGRAPHY, Male, IMPACT, Settore MED/18 - CHIRURGIA GENERALE, medicine.medical_treatment, Jejunostomy, Hepatic Duct, Common, Comorbidity, 030230 surgery, 0302 clinical medicine, Cholangiography, Older patients, Hepatic Duct, Clinical endpoint, LAPAROSCOPIC CHOLECYSTECTOMY, COMPLICATIONS, OUTCOMES, medicine.diagnostic_test, Bile duct, Gastroenterology, Hepaticojejunostomy, Middle Aged, Common, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Bile duct injuries (BDI), CLASSIFICATION, Time-to-Treatment, Biliary injury, 03 medical and health sciences, Sex Factors, HEPATIC-ARTERY INJURY, medicine, MANAGEMENT, Humans, Cholecystectomy, Aged, Retrospective Studies, Hepatology, business.industry, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, BILIARY INJURY, Surgery, Multi center study, Concomitant, RISK-FACTORS, Human medicine, Bile Ducts, business
Abstract: 13th World Biennial Congress of the International-Hepato-Pancreato-Biliary-Association (IHPBA) -- SEP 04-07, 2018 -- Geneva, SWITZERLAND, Ardito, Francesco/0000-0003-1596-2862; PESCE, ANTONIO MD/0000-0002-7560-551X; Gallagher, Tom/0000-0002-5765-2574; Bernon, Marc/0000-0002-7967-8548; Stattner, Stefan/0000-0002-5226-7597; GIULIANTE, FELICE/0000-0003-2087-2589; Omoshoro-Jones, Jones A. O./0000-0002-1071-298X; de Rose, Agostino Maria/0000-0003-3310-8088; Abu Hilal, Mohammed/0000-0002-3162-4639; Kleeff, Jorg/0000-0003-3432-6669; Prieto, Mikel/0000-0001-6662-4252; Stromberg, Cecilia/0000-0003-0843-7920, WOS: 000500283700006, PubMed: 31151812, Background: Treatment of bile duct injuries (BDI) during cholecystectomy depends on the severity of injury and the timing of diagnosis. Standard of care for severe BDIs is hepaticojejunostomy. the aim of this retrospective multi-center study was to assess the optimal timing for repair of BDI with hepaticojejunostomy. Methods: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients with hepaticojejunostomy after BDI from January 2000 to June 2016. Patients were stratified according to the timing of biliary reconstruction with hepaticojejunostomy: early (day 0-7), intermediate (1-6 weeks) and late (6 weeks-6 months). Primary endpoint was re-intervention >90 days after the hepaticojejunostomy and secondary endpoints were severe 90-day complications and liver-related mortality. Results: in total 913 patients from 48 centers were included in the analysis. in 401 patients (44%) the bile duct injury was diagnosed intraoperatively, and 126 patients (14%) suffered from concomitant vascular injury. in multivariable analysis the timing of hepaticojejunostomy had no impact on postoperative complications, the need for re-intervention after 90 days nor liver-related mortality. the rate of re-intervention more than 90 days after the hepaticojejunostomy was significantly increased in male patients but decreased in older patients. Severe co-morbidity increased the risk for liver-related mortality (HR 3.439; CI 1.37-8.65; p = 0.009). Conclusion: After BDI occurring during cholecystectomy, the timing of biliary reconstruction with hepaticojejunostomy did not have any impact on severe postoperative complications, the need for re-intervention or liver-related mortality. Individualised treatment after iatrogenic bile duct injury is still advisable., Int Hepato Pancreato Biliary Assoc
Published: 2019

36. Auction-based resource allocation in OpenFlow multi-tenant networks

Author: Salvatore D'Oro, Sergio Palazzo, Giacomo Morabito, Panayotis Mertikopoulos, Laura Galluccio, Dipartimento di Ingegneria Informatica e delle Telecomunicazioni [University of Catania] (DIIT), Università degli studi di Catania = University of Catania (Unict), University of Catania [Italy], Performance analysis and optimization of LARge Infrastructures and Systems (POLARIS ), Inria Grenoble - Rhône-Alpes, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire d'Informatique de Grenoble (LIG ), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), and Università degli studi di Catania [Catania]
Subjects: OpenFlow, Computer Networks and Communications, Computer science, Distributed computing, 02 engineering and technology, Software defined networking, symbols.namesake, 0502 economics and business, 0202 electrical engineering, electronic engineering, information engineering, Network performance, Resource management, Resource allocation, 050205 econometrics, business.industry, 05 social sciences, 020206 networking & telecommunications, Auction algorithm, Auction, Nash equilibrium, symbols, [MATH.MATH-OC]Mathematics [math]/Optimization and Control [math.OC], business, Software-defined networking, Game theory, Computer network
Abstract: International audience; In this paper, we investigate the allocation of network resources (such as FlowTable entries and bandwidth) in multi-tenant Software-Defined Networks (SDNs) that are managed by a FlowVisor. This resource allocation problem is modeled as an auction where the FlowVisor acts as the auctioneer and the network Controllers act as the bidders. The problem is analyzed by means of non-cooperative game theory, and it is shown that the auction admits a unique Nash Equilibrium (NE) under suitable conditions. Furthermore, a novel distributed learning procedure is provided that allows each Controller to reach the game’s unique NE in a few iterations by exploiting only locally available information. An implementation in OpenFlow-compliant SDNs is also proposed in a way that exploits native procedures already offered by OpenFlow. Finally, simulation results show that the proposed auction-based resource management scheme leads to significant improvements in network performance (for instance, achieving gains of up to 5 × reduction in transmission delays).
Published: 2017

37. Towards a more precise diagnosis of hypersensitivity to beta‐lactams – an EAACI position paper

Author: Jean-Christoph Roger J-P Caubet, Anca-Mirela Chiriac, Paul Whitaker, Lene H. Garvey, Annick Barbaud, Alla Nakonechna, Andreas J. Bircher, Gülfem Çelik, María José Torres, Antonino Romano, Cristobalina Mayorga, Josefina Cernadas, Pascal Demoly, Knut Brockow, Marina Atanaskovic-Markovic, University of Catania [Italy], School of Medecine [Belgrade], University of Belgrade [Belgrade], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University Hospital Basel [Basel], Department of Dermatology and Allergy Biederstein, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Geneva University Hospital (HUG), Ankara University School of Medicine [Turkey], Immunoallergy Department [Porto], Centro Hospitalar São João EPE, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Department of Clinical Medicine [Copenhagen], Bispebjerg Hospital-Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Biomedical Research Institute of Málaga (IBIMA), Universidad de Málaga [Málaga] = University of Málaga [Málaga], Allergy and Immunology Clinic [Royal Liverpool and Broadgreen University Hospital], Royal Liverpool and Broadgreen University Hospital NHS Trust, University of Liverpool, Salvy-Córdoba, Nathalie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Universidade do Porto = University of Porto, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH)
Subjects: Hypersensitivity, Immediate, medicine.medical_specialty, Allergy, [SDV.IMM] Life Sciences [q-bio]/Immunology, Referral, cross-reactivity, diagnosis, Immunology, Provocation test, Drug allergy, risk stratification, Drug Hypersensitivity, Beta-lactam, 03 medical and health sciences, chemistry.chemical_compound, Allergists, 0302 clinical medicine, medicine, Humans, Immunology and Allergy, guidelines, Child, Intensive care medicine, Skin Tests, 030304 developmental biology, 0303 health sciences, ddc:618, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, beta-lactams, Novelty, allergy, medicine.disease, Anti-Bacterial Agents, 3. Good health, 030228 respiratory system, chemistry, Risk stratification, Position paper, [SDV.IMM]Life Sciences [q-bio]/Immunology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; A recent survey of the European Academy of Allergy and Clinical Immunology (EAACI) Drug Allergy Interest Group (DAIG) on how European allergy specialists deal with beta-lactam (BL) hypersensitivity demonstrated a significant heterogeneity in current practice, suggesting the need to review and update existing EAACI guidelines in order to make the diagnostic procedures as safe and accurate, but also as cost-effective, as possible. For this purpose, a bibliographic search on large studies regarding BL hypersensitivity diagnosis was performed by an EAACI task force, which reviewed and evaluated the literature data using the GRADE system for quality of evidence and strength of recommendation. The updated guidelines provide a risk stratification in BL hypersensitivity according to index reaction(s), as well as an algorithmic approach, based on cross-reactivity studies, in patients with a suspicion of BL hypersensitivity and an immediate need for antibiotic therapy, when referral to an allergist is not feasible. Furthermore, the update addresses availability and concentrations of skin test (ST) reagents, ST and drug provocation test (DPT) protocols, as well as diagnostic algorithms and administration of alternative BL in allergic subjects. Specifically, distinct diagnostic algorithms are suggested depending on risk stratification of the patient into high and low risk based on the morphology and chronology of the reaction, immediate (i.e., occurring within 1 to 6 hours after the last administered dose) or nonimmediate (i.e., occurring more than 1 hour after the initial drug administration), and the reaction severity. Regarding the allergy workup, the main novelty of this document is the fact that in some low-risk nonimmediate reactions ST are not mandatory, especially in children. For DPT, further studies are necessary to provide data supporting the standardization of protocols, especially of those regarding nonimmediate reactions, for which there is currently no consensus.
Published: 2019

38. Development and Validation of a Nomogram for Early Detection of Malignant Gallbladder Lesions

Author: Arie Ariche, Sherry X Yang, Xiujun Cai, Fabrizio Panaro, Leandro Cardoso Barchi, Mingyu Chen, Keita Kai, Tanios Bekaii-Saab, Jian Lin, Jiasheng Cao, Yang Bai, Silvio Nadalin, Vishal Jindal, Antonio Pesce, Riccardo Memeo, Chenhao Tong, Institute of Computing Technology [Beijing] (ICT), Chinese Academy of Sciences [Changchun Branch] (CAS), Zhejiang University, Zhejiang Hospital [Hangzhou], University of Oulu, Woods Hole Oceanographic Institution (WHOI), University of Massachusetts Medical School [Worcester] (UMASS), University of Massachusetts System (UMASS), Universidade de São Paulo = University of São Paulo (USP), Internal Medicine [Tuebingen, Germany], Tuebingen University [Germany], National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), University of Catania [Italy], Service Médico-Chirurgical des Maladies de l'Appareil Digestif et de Transplantation Hépatique, Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hadassah Hebrew University Medical Center [Jerusalem], Saga University [Japon], L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, and Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA)
Subjects: Adult, Male, medicine.medical_specialty, Multivariate analysis, genetic structures, CA-19-9 Antigen, Gallbladder masses, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gallbladder cancer (GBC), Logistic regression, Cystectomy, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, medicine, Humans, Gallbladder cancer, Early Detection of Cancer, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Gallbladder, Biliary, Gastroenterology, IGBC identification, Cancer, Nomogram, Middle Aged, medicine.disease, Nomograms, medicine.anatomical_structure, ROC Curve, 030220 oncology & carcinogenesis, Radiological weapon, Cohort, Multivariate Analysis, Preoperative Period, 030211 gastroenterology & hepatology, Female, Gallbladder Neoplasms, Radiology, business, Tomography, X-Ray Computed
Abstract: International audience; OBJECTIVES:Preoperative decision-making for differentiating malignant from benign lesions in the gallbladder remains challenging. We aimed to create a diagnostic nomogram to identify gallbladder cancer (GBC), especially for incidental GBC (IGBC), before surgical resection.METHODS:A total of 587 consecutive patients with pathologically confirmed gallbladder lesions from a hospital were randomly assigned to a training cohort (70%) and an internal validation cohort (30%), with 287 patients from other centers as an external validation cohort. Radiological features were developed by the least absolute shrinkage and selection operator logistic regression model. Significant radiological features and independent clinical factors, identified by multivariate analyses, were used to construct a nomogram.RESULTS:A diagnostic nomogram was established by age, CA19.9, and 6 radiological features. The values of area under the curve in the internal and external validation cohorts were up to 0.91 and 0.89, respectively. The calibration curves for probability of GBC showed optimal agreement between nomogram prediction and actual observation. Compared with previous methods, it demonstrated superior sensitivity (91.5%) and accuracy (85.1%) in the diagnosis of GBC. The accuracy using the nomogram was significantly higher in GBC groups compared with that by radiologists in the training cohort (P < 0.001) and similarly in each cohort. Notably, most of the IGBC, which were misdiagnosed as benign lesions, were successfully identified using this nomogram.DISCUSSION:A novel nomogram provides a powerful tool for detecting the presence of cancer in gallbladder masses, with an increase in accuracy and sensitivity. It demonstrates an unprecedented potential for IGBC identification.
Published: 2019

39. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome

Author: Liliana R. V. Castro, Gwénola Poupon, Małgorzata Drozd, Pierre Vincent, Stéphane Martin, Michela Servadio, Audrey Di Giorgio, Sara Schiavi, Lara Costa, Sara Castagnola, Sébastien Delhaye, Anouar Khayachi, Élia Mota, Lara Maria Sardone, Viviana Trezza, Barbara Bardoni, Stéphane Azoulay, Francesca Melancia, Marielle Jarjat, Thomas Maurin, Lucia Ciranna, Institut de pharmacologie moléculaire et cellulaire (IPMC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Laboratoire International Associé 'Neogenex' (LIA Neogenex), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-St Jude Children's Research Hospital-Hôpital Pequeño Principe, Department of Sciences [Roma, Italy], Università degli Studi Roma Tre, Adaptation Biologique et Vieillissement = Biological Adaptation and Ageing (B2A), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Labex BioPsy [Paris, France], Department of Clinical and Experimental Medicine [Messina, Italy], University of Messina, Institut de Chimie de Nice (ICN), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Department of Biomedical and Biotechnological Sciences [Catania, Italy], University of Catania [Italy], Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), St Jude Children's Research Hospital-Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Hôpital Pequeño Principe, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Università degli Studi Roma Tre = Roma Tre University (ROMA TRE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Martin, Stephane, Maurin, T., Melancia, F., Jarjat, M., Castro, L., Costa, L., Delhaye, S., Khayachi, A., Castagnola, S., Mota, E., Giorgio, A. D., Servadio, M., Drozd, M., Poupon, G., Schiavi, S., Sardone, L., Azoulay, S., Ciranna, L., Martin, S., Vincent, P., Trezza, V., and Bardoni, B.
Subjects: Dendritic spine, Phosphodiesterase Inhibitors, [SDV]Life Sciences [q-bio], Hippocampal formation, Phosphodiesterase Inhibitor, Receptors, Metabotropic Glutamate, Hippocampus, Gene Knockout Techniques, Fragile X Mental Retardation Protein, Mice, 0302 clinical medicine, Intellectual disability, Translational regulation, Cyclic AMP, Phosphodiesterase 2A, Autism spectrum disorder, fragile X syndrome, Cyclic GMP, Neurons, Mice, Knockout, Triazines, 05 social sciences, Imidazoles, Gene Knockout Technique, Phosphodiesterase, Fragile X syndrome, [SDV] Life Sciences [q-bio], Triazine, medicine.medical_specialty, congenital, hereditary, and neonatal diseases and abnormalities, phosphodiesterase 2A, Dendritic Spines, Cognitive Neuroscience, Primary Cell Culture, autism spectrum disorder, 050105 experimental psychology, 03 medical and health sciences, Cellular and Molecular Neuroscience, Hippocampu, Dendritic Spine, Internal medicine, medicine, Animals, 0501 psychology and cognitive sciences, Social Behavior, Imidazole, business.industry, Animal, Long-Term Synaptic Depression, Excitatory Postsynaptic Potentials, Neuron, medicine.disease, Embryo, Mammalian, Cyclic Nucleotide Phosphodiesterases, Type 2, autism spectrum disorder, Fmr1-KO mice, Fmr1-KO rats, fragile X syndrome, phosphodiesterase 2A, Fmr1-KO rats, Rats, nervous system diseases, Animal Communication, Endocrinology, Fmr1-KO rat, Animals, Newborn, Excitatory Postsynaptic Potential, Fragile X Syndrome, Autism, Rat, business, Fmr1-KO mice, 030217 neurology & neurosurgery
Abstract: The fragile X mental retardation protein (FMRP) is an RNA-binding protein involved in translational regulation of mRNAs that play key roles in synaptic morphology and plasticity. The functional absence of FMRP causes the fragile X syndrome (FXS), the most common form of inherited intellectual disability and the most common monogenic cause of autism. No effective treatment is available for FXS. We recently identified the Phosphodiesterase 2A (Pde2a) mRNA as a prominent target of FMRP. PDE2A enzymatic activity is increased in the brain of Fmr1-KO mice, a recognized model of FXS, leading to decreased levels of cAMP and cGMP. Here, we pharmacologically inhibited PDE2A in Fmr1-KO mice and observed a rescue both of the maturity of dendritic spines and of the exaggerated hippocampal mGluR-dependent long-term depression. Remarkably, PDE2A blockade rescued the social and communicative deficits of both mouse and rat Fmr1-KO animals. Importantly, chronic inhibition of PDE2A in newborn Fmr1-KO mice followed by a washout interval, resulted in the rescue of the altered social behavior observed in adolescent mice. Altogether, these results reveal the key role of PDE2A in the physiopathology of FXS and suggest that its pharmacological inhibition represents a novel therapeutic approach for FXS.
Published: 2019

40. Marginal Agricultural Land Low-Input Systems for Biomass Production

Author: Ian McCallum, Igor Staritsky, Efthymia Alexopoulou, Moritz von Cossel, Santa Neimane, Federica Zanetti, J.E. Carrasco, Salvatore Luciano Cosentino, Danilo Scordia, Dagnija Lazdina, Giorgio Testa, Ana Luisa Fernando, Eleni G. Papazoglou, Michiel van Eupen, Oksana Maliarenko, Yasir Iqbal, Andrea Monti, Stefan Mantel, Pilar Ciria, Eibertus N. van Loo, Luisa M. Trindade, Lisa Ciadamidaro, Ioannis Eleftheriadis, Isabelle Lamy, Iris Lewandowski, Berien Elbersen, Marina Sanz, Wolter Elbersen, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), DCTB - Departamento de Ciências e Tecnologia da Biomassa (ex-GDEH), MEtRICS - Centro de Engenharia Mecânica e Sustentabilidade de Recursos, Cossel M.V., Lewandowski I., Elbersen B., Staritsky I., Van Eupen M., Iqbal Y., Mantel S., Scordia D., Testa G., Cosentino S.L., Maliarenko O., Eleftheriadis I., Zanetti F., Monti A., Lazdina D., Neimane S., Lamy I., Ciadamidaro L., Sanz M., Carrasco J.E., Ciria P., McCallum I., Trindade L.M., Van Loo E.N., Elbersen W., Fernando A.L., Papazoglou E.G., Alexopoulou E., Von Cossel, Moritz, University of Hohenheim, Wageningen Environmental Research, Wageningen University and Research [Wageningen] (WUR), Hunan Agricultural University, International Soil Reference and Information Centre, Partenaires INRAE, University of Catania [Italy], Institute of Bioenergy Crops and Sugar Beet NAAS, Center for Renewable Energy Sources, Biomass Department, Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Latvian State Forest Research Institute 'Silava', Ecologie fonctionnelle et écotoxicologie des agroécosystèmes (ECOSYS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Université Paris Saclay (COmUE), Centro de Investigaciones Energéticas Medioambientales y Tecnológicas [Madrid] (CIEMAT), International Institute for Applied Systems Analysis (IIASA), Laboratory of plant breeding, Plant Breeding, Wageningen Food & Biobased Research, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), and Agricultural University of Athens
Subjects: bioeconomy, bio-based industry, biomass, bioenergy, industrial crop, perennial crop, low-input agriculture, marginal land, MALLIS, sustainable agriculture, Bio-based industry, Applied Spatial Research, [SDV]Life Sciences [q-bio], Biomass, 02 engineering and technology, lcsh:Technology, 7. Clean energy, Bioma, Laboratorium voor Plantenveredeling, Agricultural land, agriculture, Aardobservatie en omgevingsinformatica, Sustainable agriculture, 0202 electrical engineering, electronic engineering, information engineering, Bioenergy, SDG 15 - Life on Land, 2. Zero hunger, Marginal land, biology, Agroforestry, Low-input agriculture, 04 agricultural and veterinary sciences, Miscanthus, Bioeconomy, [SDE]Environmental Sciences, BBP Biorefinery & Sustainable Value Chains, ISRIC - World Soil Information, Earth Observation and Environmental Informatics, Control and Optimization, 020209 energy, Energy Engineering and Power Technology, Perennial crop, SDG 7 - Affordable and Clean Energy, Electrical and Electronic Engineering, SDG 2 - Zero Hunger, Engineering (miscellaneous), lcsh:T, Renewable Energy, Sustainability and the Environment, business.industry, 15. Life on land, Sorghum, biology.organism_classification, Plant Breeding, Industrial crop, Agriculture, 040103 agronomy & agriculture, 0401 agriculture, forestry, and fisheries, Environmental science, EPS, business, Energy (miscellaneous)
Abstract: This study deals with approaches for a social-ecological friendly European bioeconomy based on biomass from industrial crops cultivated on marginal agricultural land. The selected crops to be investigated are: Biomass sorghum, camelina, cardoon, castor, crambe, Ethiopian mustard, giant reed, hemp, lupin, miscanthus, pennycress, poplar, reed canary grass, safflower, Siberian elm, switchgrass, tall wheatgrass, wild sugarcane, and willow. The research question focused on the overall crop growth suitability under low-input management. The study assessed: (i) How the growth suitability of industrial crops can be defined under the given natural constraints of European marginal agricultural lands; and (ii) which agricultural practices are required for marginal agricultural land low-input systems (MALLIS). For the growth-suitability analysis, available thresholds and growth requirements of the selected industrial crops were defined. The marginal agricultural land was categorized according to the agro-ecological zone (AEZ) concept in combination with the marginality constraints, so-called 'marginal agro-ecological zones' (M-AEZ). It was found that both large marginal agricultural areas and numerous agricultural practices are available for industrial crop cultivation on European marginal agricultural lands. These results help to further describe the suitability of industrial crops for the development of social-ecologically friendly MALLIS in Europe. publishersversion published
Published: 2019
Full Text: View/download PDF

41. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

Author: Marco Valgimigli, Takeshi Kimura, Robert W. Yeh, Martin B. Leon, Dominick J. Angiolillo, Roxana Mehran, Mitchell W. Krucoff, Stuart J. Pocock, Yoshiaki Mitsutake, Ernest Spitzer, P. F.Adrian Magee, Andrew Farb, Akihide Konishi, Matthew J. Price, Davide Capodanno, Olivier Varenne, Ute Windhoevel, Roisin Colleran, Philip Urban, C. Michael Gibson, Darren Mylotte, Donald E. Cutlip, Thomas Cuisset, Hyo-Soo Kim, John C. Laschinger, Stefan James, Michael Haude, John Gregson, Marie Claude Morice, John Eikelboom, Norman Stockbridge, Sunil V. Rao, Pedro Eerdmans, Robert A. Byrne, Hôpital de la Tour, Cardiovascular Research Foundation, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University of Florida [Gainesville] (UF), University of Catania [Italy], Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital de la Timone [CHU - APHM] (TIMONE), Harvard Medical School [Boston] (HMS), AUTRES, McMaster University [Hamilton, Ontario], U.S. Food and Drug Administration (FDA), London School of Hygiene and Tropical Medicine (LSHTM), Lukaskrankenhaus, Uppsala University, Seoul National University Hospital, Kyoto University, Pharmaceuticals and Medical Devices Agency, Columbia University [New York], National University of Ireland [Galway] (NUI Galway), Scripps Clinic [San Diego, CA, USA], Duke Clinical Research Institute, Duke University Medical Center, Erasmus University Medical Center [Rotterdam] (Erasmus MC), University of Bern, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cardiovascular European Research Center, Beth Israel Deaconess Medical Center [Boston] (BIDMC), Hôpital Privé Jacques Cartier [Massy], The ARC-HBR group was entirely funded by multiple industry sponsors. Sponsors participated as observers in both meetings and were provided a copy of the document before submission. The contributing companies were Abbott Vascular, Alvimedica, Amgen, AstraZeneca, Biosensors, Biotronik, Boston Scientific, Celonova, Chiesi, Cordis, Daiichi Sankyo, Edwards Lifesciences, Janssen, Medinol, Medtronic, Orbusneich, Portola, Sanofi, Sinomed, Sahajanand Medical Technologies, and Terumo.Conflict of interest: Dr Colleran received financial compensation for her contribution to the preparation of this document. In accordance with the ARC charter, none of the other participants received fees or honoraria for their participation in the meetings or their contribution to this document. Dr Urban reports receiving speaker and consulting honoraria as an individual from Biosensors-Europe, Sinomed, and Terumo, participating in paid review activities (Clinical End Point Committee, Data Safety Monitoring Board) for Edward Lifesciences, Terumo, and Abbott Vascular, and serving as a medical codirector at the Cardiovascular European Research Center, a contract research organization based in Massy, France. Dr Mehran reports consultant fees to the institution from Abbott Laboratories and Spectranetics/Philips/Valcano Corp, consulting fees from Boston Scientific, Cardiovascular Systems Inc, Medscape, Siemens Medical Solutions, Regeneron Pharmaceuticals Inc, Roivant Sciences Inc, and Sanofi, being the spouse of a consultant for Abiomed and The Medicines Company, research funding to the institution from AstraZeneca, Bayer, Beth Israel Deaconess Hospital, BMS, CSL Behring, Eli Lilly and DSI, Medtronic, Novartis Pharmaceuticals, and Orbus Neich, scientific advisory board fees from PLx Opco Inc, dba PLx Pharma Inc, scientific advisory board fees to the institution from Bristol-Myers Squibb, executive committee fees from Janssen Pharmaceuticals and Osprey Medical, speaker engagements for Abbott Laboratories, equity from Claret Medical and Elixir Medical, and Data Safety Monitoring Board fees to the institution from Atermark Research Partners. Dr Angiolillo reports payments, consulting fees, or honoraria from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PLx Pharma Inc, Pfizer, Sanofi, and The Medicines Company, fees for participation in review activities from CeloNova and St. Jude Medical, institutional grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Matsutani Chemical Industry Co, Merck, Novartis, Osprey Medical, and Renal Guard Solutions, and funding from the Scott R. MacKenzie Foundation and the National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Award to the University of Florida UL1 TR000064 and National Institutes of Health/National Human Genome Research Institute U01 HG007269. Dr Byrne reports lecture fees from B. Braun Melsungen AG, Biotronik, Boston Scientific, and Micell Technologies and research funding to the institution from Boston Scientific and Celonova Biosciences. Dr Capodanno reports personal fees from Abbott Vascular, Bayer, Daiichi Sankyo, Pfizer, and AstraZeneca. Dr Cutlip reports receiving consultant fees from Celonova Biosciences and academic salary support from the Baim Institute for Clinical Research, an academic research organization in Boston, MA. Dr Eikelboom reports consulting fees and grant support from AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, Pfizer, Janssen, and Sanofi-Aventis. Dr Gibson reports being chief executive officer of the Baim Institute for Clinical Research, in addition to receiving research grant funding from Angel Medical Corp, Bayer Corp, CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corp, and Portola Pharmaceuticals, consultant fees from Amarin Pharama, Amgen, Bayer Corp, Boehringer Ingelheim, Boston Clinical Research Institute, Boston Scientific, Cardiovascular Research Foundation, CSL Behring, Chiesi, Duke Clinical Research Institute, Eli Lilly and Company, Gilead Sciences, Inc, Impact Bio LTD, Janssen Pharmaceuticals, Johnson & Johnson Corp, The Medicines Company, MedImmune, Medtelligence, Merck & Co, Inc, Microport, Novo Nordisk, PERT Consortium, Pharma Mar, Portola Pharmaceuticals, Sanofi, Somahlution, Vereseon Corporation, and Web MD, and royalties as a contributor from UpToDate in Cardiovascular Medicine. Dr Gregson reports personal fees from Edwards Lifesciences, MvRX, Amarin Corp, and BioSensors. Dr Haude reports grant support from Biotronik, Orbus Neich, AbboF, Medtronic, and Cardiac Dimensions, speaker’s bureau fees from Biotronik, Orbus Neich, AbboF, Medtronic, Lilly, Philips/ Volcano, and Cardiac Dimensions (Proctor), and consultant fees from Biotronik, Orbus Neich, and AbboF. Dr James reports institutional research grants from AstraZeneca, Bayer, Jansen, The Medicines Company, Abbot Vascular, and Boston Scientific, as well as honoraria from AstraZeneca, Bayer, and Medtronic. Dr Kimura reports consulting fees or honoraria from Abbott Vascular Japan Co, Ltd, Kowa Co, Ltd, Kowa Pharmaceutical Co Ltd, Sanofi K.K., Nippon Boehringer Ingelheim Co, Ltd, and Bristol-Myers Squibb K.K., as well as grant support from Otsuka Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Mitsubishi Tanabe Pharma Corp, Takeda Pharmaceutical Co Ltd, and Nippon Boehringer Ingelheim Co, Ltd. Dr Leon reports receiving research grants from Abbott Vascular, Boston Scientific, Medtronic, Biosensors, and SinomedEquity-Medinol. Dr Mylotte reports speaker fees from Biosensors and institutional research grants from Biosensors and Medtronic. Dr Pocock has served on steering committees or data monitoring committees for trials sponsored by AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Idorsia, Janssen, Medtronic, Novartis, Novo Nordisk, and Vifor, and has received grant funding from AstraZeneca and Merck. Dr Price reports receiving consulting honoraria from AstraZeneca, Chiesi USA, Medtronic, Boston Scientific, and Abbott Vascular/St Jude Medical, speaker’s bureau/fees from AstraZeneca, Chiesi USA, Medtronic, Boston Scientific, Abbott Vascular/St Jude Medical, and ACIST Medical, and institutional research grants from Daiichi-Sankyo. Dr Valgimigli reports grants and personal fees from Abbott, AstraZeneca, and Terumo, personal fees from Chiesi, Bayer, Daiichi Sankyo, Amgen, Alvimedica, Biosensors, and Idorsia, and grants from Medicure. Dr Varenne reports receiving consulting and research grants from Boston Scientific, Abbott Vascular, AstraZeneca, and Servier. Dr Yeh reports consulting and research grants from Abbott Vascular and Boston Scientific, research grants from Abiomed and AstraZeneca, and consulting fees from Biosense Webster, Medtronic, and Teleflex. Dr Krucoff reports receiving consulting and research grants from Abbott Vascular, Biosensors, Boston Scientific, Cook Medical, Medtronic, and OrbusNeich. Dr Morice is the chief executive officer of the Cardiovascular European Research Center, the contract research organization organizing the ARC-HBR initiative. The other authors report no conflicts., Kyoto University [Kyoto], Cardiology, and Prémilleux, Annick
Subjects: Percutaneous, protocole de recherche, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Cardiologie et système cardiovasculaire, 030204 cardiovascular system & hematology, 0302 clinical medicine, maladie coronaire, Cardiac and Cardiovascular Systems, 030212 general & internal medicine, Aged, 80 and over, education.field_of_study, Clinical Trials as Topic, Kardiologi, Frailty, hémorragie, European research, Dual Anti-Platelet Therapy, Anemia, Drug-Eluting Stents, 3. Good health, ddc, Europe, [SDV] Life Sciences [q-bio], Treatment Outcome, Current Opinion, Metals, Stents, clinical trial protocols as topic, Safety, hemorrhage, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Asia, Consensus, Population, Clinical Decision-Making, 610 Medicine & health, Risk Assessment, Medication Adherence, Food and drug administration, 03 medical and health sciences, Physiology (medical), Hypertension, Portal, medicine, Humans, In patient, Acute Coronary Syndrome, Renal Insufficiency, Chronic, Intensive care medicine, education, Aged, business.industry, percutaneous coronary intervention, Percutaneous coronary intervention, Data interpretation, Fibrosis, Thrombocytopenia, United States, Clinical trial, Cardiology and cardiovascular system, business
Abstract: Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention–related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.
Published: 2019

42. Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Author: Maria Grazia Rumi, Laurent Alric, Francesco Passamonti, Dario Marino, Virginia Valeria Ferretti, Isabel Cano, Michele Merli, Manuel Gotti, Roberta Sciarra, Maria Chiara Tisi, Paolo Grossi, Véronique Loustaud-Ratti, Angela Ferrari, Alice Di Rocco, Carlo Visco, Maria Goldaniga, Chiara Rusconi, Emanuele Cencini, F. Benanti, Antonello Sica, Massimo Gentile, Marco Frigeni, Luca Arcaini, Lucia Farina, Francesco Piazza, Annalisa Arcari, Valentina Zuccaro, Lara Mannelli, Caroline Besson, Mario Pirisi, Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Università degli Studi di Pavia = University of Pavia (UNIPV), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Ospedale San Bortolo, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Azienda Ospedaliera Careggi, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Azienda Unita` Sanitaria Locale, Azienda Unita` Sanitaria Locale, La Spezia, IRCCS Istituto Nazionale dei Tumori [Milano], University of Piemonte Orientale, Partenaires INRAE, Università degli Studi di Padova = University of Padua (Unipd), Université de Limoges (UNILIM), Azienda Unità Sanitaria Locale di Bologna (AUSL), Veneto Institute of Oncology, IOV - IRCCS, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ospedale Niguarda Ca' Granda Hospital, Università degli Studi di Siena = University of Siena (UNISI), University of Catania [Italy], Università degli Studi di Milano = University of Milan (UNIMI), Fondazione IRCCS Policlinico San Matteo, Service d’Hématologie et d’Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France, Pagès, Nathalie, University of Insubria, Varese, University of Pavia, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], University of Padova [Padova, Italy], University of Siena (University of Siena), University of Milan, Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)
Subjects: Male, Cancer Research, Sofosbuvir, Diffuse large B‐cell lymphoma, Hematologic Malignancies, [SDV]Life Sciences [q-bio], Direct‐acting antivirals, Hepatitis C virus, R‐CHOP, Hepacivirus, Direct-acting antivirals, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Aged, 80 and over, Dasabuvir, Incidence, Hepatitis C, Diffuse large B-cell lymphoma, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 3. Good health, [SDV] Life Sciences [q-bio], [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Italy, Oncology, Vincristine, R-CHOP, 030220 oncology & carcinogenesis, Rituximab, Female, Lymphoma, Large B-Cell, Diffuse, medicine.drug, Ledipasvir, Adult, medicine.medical_specialty, Antiviral Agents, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Progression-free survival, Cyclophosphamide, Aged, Retrospective Studies, business.industry, Ribavirin, Hepatitis C, Chronic, medicine.disease, chemistry, Paritaprevir, Doxorubicin, Prednisone, business
Abstract: International audience; Background: International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported.Subjects, materials, and methods: We analyzed hematological and virological outcome and survival of 47 consecutive patients with HCV-positive DLBCL treated at 23 Italian and French centers with DAAs either concurrently (concurrent cohort [ConC]: n = 9) or subsequently (sequential cohort [SeqC]: n = 38) to first-line I-CT (mainly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP]-like).Results: Median age was 61 years, 89% of patients had stage III/IV, and 25% presented evidence of cirrhosis. Genotype was 1 in 56% and 2 in 34% of cases. Overall, 46 of 47 patients obtained complete response to I-CT. All patients received appropriate DAAs according to genotype, mainly sofosbuvir-based regimens (n = 45). Overall, 45 patients (96%) achieved sustained virological response, 8 of 9 in ConC and 37 of 38 in SeqC. DAAs were well tolerated, with only 11 patients experiencing grade 1-2 adverse events. Twenty-three patients experienced hepatic toxicity (grade 3-4 in seven) following I-CT in SeqC, compared to only one patient in ConC. At a median follow-up of 2.8 years, two patients died (2-year overall survival, 97.4%) and three progressed (2-year progression-free survival, 93.1%).Conclusion: Excellent outcome of this cohort of HCV-positive DLBCL suggests benefit of HCV eradication by DAAs either after or during I-CT. Moreover, concurrent DAAs and R-CHOP administration appeared feasible, effective, and ideally preferable to deferred administration of DAAs for the prevention of hepatic toxicity.Implications for practice: Hepatitis C virus (HCV)-associated diffuse large B-cell lymphomas (DLBCLs) represent a great therapeutic challenge, especially in terms of hepatic toxicity during immune-chemotherapy (I-CT) and long-term hepatic complications. The advent of highly effective and toxicity-free direct-acting antivirals (DAAs) created an exciting opportunity to easily eradicate HCV shortly after or in concomitance with first-line immunochemotherapy (usually R-CHOP). This retrospective international study reports the real-life use of the combination of these two therapeutic modalities either in the concurrent or sequential approach (DAAs after I-CT) in 47 patients. The favorable reported results on long-term outcome seem to support the eradication of HCV with DAAs in all patients with HCV-positive DLBCL. Moreover, the results from the concurrent approach were effective and safe and displayed an advantage in preventing hepatic toxicity during I-CT.
Published: 2019

43. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

Author: Caroline Lavie, Fabien Rollot, Françoise Durand-Dubief, Romain Marignier, Iuliana Ionescu, Romain Casey, Thibault Moreau, Patricia Tourniaire, Michael Hutchinson, Marie Béatrice D’Hooghe, David-Axel Laplaud, Pierre Clavelou, Jérôme De Sèze, Marc Debouverie, David Brassat, Jean Pelletier, Christine Lebrun-Frenay, Emmanuelle Le Page, Giovanni Castelnovo, Eric Berger, Patrick Hautecoeur, Olivier Heinzlef, Luca Durelli, Marinella Clerico, Maria Trojano, Francesco Patti, Sandra Vukusic, A. Alpérovitch, H. Carton, M.B. d’Hooghe, O. Hommes, M. Hutchinson, P. Adeleine, A. Biron, P. Cortinovis-Tourniaire, J. Grimaud, M. Hours, T. Moreau, S. Vukusic, C. Confavreux, G. Chauplannaz, D. Latombe, M. Clanet, G. Lau, L. Rumbach, J.Y. Goas, F. Rouhart, A. Mazingue, E. Roullet, M. Madigand, P. Hautecoeur, P. Brunet, G. Edan, C. Allaire, G. Riffault, J. Leche, T. Benoit, C. Simonin, F. Ziegler, J.C. Baron, Y. Rivrain, R. Dumas, D. Loche, J.C. Bourrin, B. Huttin, B. Delisse, I. Gibert, C. Boulay, M. Verceletto, G. Durand, G. Bonneviot, R. Gil, M.A. Hedreville, C. Belair, R.J. Poitevin, J.L. Devoize, P. Wyremblewski, F. Delestre, A. Setiey, G. Comi, M. Filippi, A. Ghezzi, V. Martinelli, P. Rossi, M. Zaffaroni, M.R. Tola, M.P. Amato, C. Fioretti, G. Meucci, M. Inglese, G.L. Mancardi, D. Gambi, A. Thomas, M. Cavazzuti, A. Citterio, A. Heltberg, H.J. Hansen, O. Fernandez, F. Romero, T. Arbizu, J.J. Hernandez, C. De Andres de Frutos, D. Geffner Sclarky, Y. Aladro Benito, P. Reyes Yanes, M Aguilar, J.A. Burguera, R. Yaya, W. Bonakim Dib, D. Arzua-Mouronte, C.J.M. Sindic, R. Medaer, H. Roose, K.M.J. Geens, D. Guillaume, M. Van Zandycke, J. Janssens, M. Cornette, L. Mol, F. Weilbach, P. Flachenecker, H.P. Hartung, J. Haas, I. Tendolkar, E. Sindrn, H.W. Kölmel, D. Reichel, M. Rauch, S. Preuss, S. Poser, E. Mauch, S. Strausser-Fuchs, H. Kolleger, S. Hawkins, S.J.L. Howell, J.E. Rees, A. Thompson, M. Johnson, M. Boggild, R.P. Gregory, D. Bates, I. Bone, C. Polman, S. Frequin, P. Jongen, J. Correia de Sa, M.E. Rio, S. Huber, J. Lechner-Scott, L. Kappos, I. Ionescu, C. Cornu, M. El-Etr, E.E. Baulieu, M Schumacher, D.H. Miller, M. Pugeat, C. d’Archangues, J. Conard, J. Ménard, R. Sitruk-Ware, C. Pelissier, S. Dat, J. Belaïsch-Allard, N. Athéa, D. Büschsenschutz, O. Lyon-Caen, R. Gonsette, J.P. Boissel, P. Ffrench, F. Durand-Dubief, F. Cotton, C. Pachai, L. Bracoud, G. Androdias, R. Marignier, D.A. Laplaud, S. Wiertlewski, C. Lanctin-Garcia, G. Couvreur, G. Madinier, P. Clavelou, F. Taithe, D. Aufauvre, N. Guy, A. Ferrier, J. De Sèze, N. Collongues, M. Debouverie, F. Viala, D. Brassat, A. Gerdelat-Mas, P. Henry, J. Pelletier, A. Rico-Lamy, C. Lebrun-Frenay, E. Lepage, V. Deburghraeve, G. Castelnovo, E. Berger, M. Blondiau, O. Heinzlef, M. Coustans, C. Clerc, L. Rieu, M. Lauxerois, G. Hinzelin, J.C. Ouallet, D. Minier, P. Vion, N. Gromaire-Fayolle, N. Derache, E. Thouvenot, M. Sallansonnet-Froment, P. Tourniaire, L. Toureille, F. Borgel, B. Stankoff, C. Moroianu, A.M. Guennoc, C.L. Tournier-Gervason, S. Peysson, M. Trojano, F. Patti, E. D’Amico, L. Motti, L. Durelli, A. Tavella, Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL), Observatoire Français de la Sclérose En Plaques [Lyon] (OFSEP), Service de neurologie fonctionnelle et d'épileptologie [Hôpital Pierre Wertheimer-HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Henri Duffaut (Avignon), National MS Center Melsbroek, Vrije Universiteit Brussel [Bruxelles] (VUB), Vrije Universiteit Brussel (VUB), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de Neurologie [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand-CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Laboratoire de Neuroimagerie in Vivo (LNV), CHU Strasbourg-Centre National de la Recherche Scientifique (CNRS), Les Hôpitaux Universitaires de Strasbourg (HUS), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Neurologie vasculaire, pathologie neuro-dégénérative et explorations fonctionnelles du système nerveux [Toulouse], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Universitaire de Nice (CHU Nice), Université Côte d'Azur (UCA), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Università degli studi di Torino = University of Turin (UNITO), University of Catania [Italy], Hospices Civils de Lyon, Departement de Neurologie (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Protéines membranaires transductrices d'énergie (PMTE), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Institut des Géosciences de l’Environnement (IGE), Institut de Recherche pour le Développement (IRD)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre de Recherches sur les Macromolécules Végétales (CERMAV ), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Environnement Ville Société (EVS), École normale supérieure - Lyon (ENS Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet [Saint-Étienne] (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), Solvay (France), Laboratoire des Mécanismes et Transfert en Géologie (LMTG), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS), Institute of Evolutionary Biology, University of Edinburgh, Université de Lille, Sciences et Technologies, Service de Génétique Médicale [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Différenciation, interaction, activation et migration des sous-populations lymphocitaires humaines, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Motricité, interactions, performance EA 4334 / Movement - Interactions - Performance (MIP), Le Mans Université (UM)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR des Sciences et Techniques des Activités Physiques et Sportives (UFR STAPS), Laboratoire Ecologie Fonctionnelle et Environnement (ECOLAB), Institut Ecologie et Environnement (INEE), Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Météo-France -Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Laboratoire de Chimie Physique D'Orsay (LCPO), Université Paris-Sud - Paris 11 (UP11)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), RMN et optique : De la mesure au biomarqueur, Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Department of Neurology, CHU Lyon, Institut de Recherche de Chimie Paris (IRCP), Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ministère de la Culture (MC), Hôpital de Hautepierre [Strasbourg], Laboratoire de Réactivité des Surfaces et des Interfaces (LRSI), Département de Physico-Chimie (DPC), CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-CEA-Direction des Energies (ex-Direction de l'Energie Nucléaire) (CEA-DES (ex-DEN)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Empenn, Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes 1 (UR1), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, European Leukodystrophies Association, PHRC National, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pierre Wertheimer, Département de Neurologie, Laboratoire de Mathématiques (LAMA), Centre National de la Recherche Scientifique (CNRS)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry]), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Nottingham Scientific Limited, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Turin, Università degli studi di Torino (UNITO), University of Bari Aldo Moro (UNIBA), Department of Neurosciences, Università degli studi di Catania [Catania], Centre de recherche en neurosciences de Lyon (CRNL), Neuroépidémiologie, Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut de Recherche pour le Développement (IRD)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-École nationale supérieure d'architecture de Lyon (ENSAL)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École Nationale des Travaux Publics de l'État (ENTPE)-Université Jean Monnet [Saint-Étienne] (UJM)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Météo France-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut Ecologie et Environnement (INEE), Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Observatoire Midi-Pyrénées (OMP), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ministère de la Culture (MC), Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Bretagne Sud (UBS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Lavie, Caroline, Rollot, Fabien, Durand-Dubief, Françoise, Marignier, Romain, Ionescu, Iuliana, Casey, Romain, Moreau, Thibault, Tourniaire, Patricia, Hutchinson, Michael, D’Hooghe, Marie Béatrice, Laplaud, David-Axel, Clavelou, Pierre, De Sèze, Jérôme, Debouverie, Marc, Brassat, David, Pelletier, Jean, Lebrun-Frenay, Christine, Le Page, Emmanuelle, Castelnovo, Giovanni, Berger, Eric, Hautecoeur, Patrick, Heinzlef, Olivier, Durelli, Luca, Clerico, Marinella, Trojano, Maria, Patti, Francesco, Vukusic, Sandra, on behalf of PRIMS and POPARTMUS, Investigator, Filippi, Massimo, Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy], Environnement, Ville, Société (EVS), École normale supérieure de Lyon (ENS de Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Neuroimagerie: méthodes et applications (Empenn), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Laboratoire de glaciologie et géophysique de l'environnement (LGGE), Observatoire des Sciences de l'Univers de Grenoble (OSUG), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherches sur les Macromolécules Végétales (CERMAV), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Laboratoire Motricité, Interactions, Performance, Université de Nantes (UN), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Ministère de la Culture (MC), Centre Hospitalier Universitaire de Strasbourg (CHU de Strasbourg ), CEA-Direction de l'Energie Nucléaire (CEA-DEN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-CEA-Direction de l'Energie Nucléaire (CEA-DEN), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Service de neurologie [Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Service de Neurologie [CHU Besançon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Service de Neurologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Clinical sciences, Neuroprotection & Neuromodulation, and Neurology
Subjects: relapses, Neurology, [SDV]Life Sciences [q-bio], MESH: Pregnancy Complications / physiopathology, 0302 clinical medicine, MESH: Pregnancy, Anesthesia, Conduction, Recurrence, MESH: Anesthesia, Conduction / adverse effects, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, reproductive and urinary physiology, relapse, Postpartum Period, post-partum, MESH: Follow-Up Studies, MESH: Multiple Sclerosis / physiopathology, Obstetrical Analgesia, MESH: Multiple Sclerosis / chemically induced, Anesthesia, Female, pregnancy, Adult, medicine.medical_specialty, Clinical Neurology, Multiple sclerosis, MESH: Postpartum Period, 03 medical and health sciences, medicine, Humans, Multiple sclerosi, Post partum, Retrospective Studies, Pregnancy, MESH: Humans, MESH: Pregnancy Complications / chemically induced, business.industry, Neurotoxicity, MESH: Adult, MESH: Retrospective Studies, neuraxial analgesia, medicine.disease, MESH: Recurrence, Multiple sclerosis, neuraxial analgesia, post-partum, pregnancy, Pregnancy Complications, Increased risk, Neurology (clinical), [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract: Background: Obstetrical analgesia remains a matter of controversy because of the fear of neurotoxicity of local anesthetics on demyelinated fibers or their potential relationship with subsequent relapses. Objective: To assess the impact of neuraxial analgesia on the risk of relapse during the first 3 months post-partum, with a focus on women who experienced relapses during pregnancy. Methods: We analyzed data of women followed-up prospectively during their pregnancies and at least 3 months post-partum, collected in the Pregnancy in Multiple Sclerosis (PRIMS) and Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPARTMUS) studies between 1992–1995 and 2005–2012, respectively. The association of neuraxial analgesia with the occurrence of a post-partum relapse was estimated by logistic regression analysis. Results: A total of 389 women were included, 215 from PRIMS and 174 from POPARTMUS. In total, 156 women (40%) had neuraxial analgesia. Overall, 24% experienced a relapse during pregnancy and 25% in the 3 months post-partum. Women with a pregnancy relapse were more likely to have a post-partum relapse (odds ratio (OR) = 1.83, p = 0.02), independently of the use of neuraxial analgesia. There was no association between neuraxial analgesia and post-partum relapse (OR = 1.08, p = 0.78). Conclusion: Neuraxial analgesia was not associated with an increased risk of post-partum relapses, whatever multiple sclerosis (MS) activity during pregnancy.
Published: 2019

44. Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease

Author: Chiesa P. A., Cavedo E., Vergallo A., Lista S., Potier M. -C., Habert M. -O., Dubois B., Thiebaut de Schotten M., Hampel H., Audrain C., Auffret A., Bakardjian H., Baldacci F., Batrancourt B., Benakki I., Benali H., Bertin H., Bertrand A., Boukadida L., Cacciamani F., Causse V., Cherif Touil S., Colliot O., Dalla Barba G., Depaulis M., Dos Santos A., Dubois M., Epelbaum S., Fontaine B., Francisque H., Gagliardi G., Genin A., Genthon R., Glasman P., Gombert F., Habert M. O., Hewa H., Houot M., Jungalee N., Kas A., Kilani M., La Corte V., Le Roy F., Lehericy S., Letondor C., Levy M., Lowrey M., Ly J., Makiese O., Masetti I., Mendes A., Metzinger C., Michon A., Mochel F., Nait Arab R., Nyasse F., Perrin C., Poirier F., Poisson C., Potier M. C., Ratovohery S., Revillon M., Rojkova K., Santos-Andrade K., Schindler R., Servera M. C., Seux L., Simon V., Skovronsky D., Uspenskaya O., Vlaincu M., Aguilar L. F., Babiloni C., Benda N., Black K. L., Bokde A. L. W., Bonuccelli U., Broich K., Cacciola F., Castrillo J., Ceravolo R., Corvol J. -C., Claudio Cuello A., Cummings J. L., Depypere H., Duggento A., Durrleman S., Escott-Price V., Federoff H., Teresa Ferretti M., Fiandaca M., Frank R. A., Garaci F., Geerts H., George N., Giorgi F. S., Graziani M., Haberkamp M., Herholz K., Karran E., Kim S. H., Koronyo Y., Koronyo-Hamaoui M., Lamari F., Langevin T., Lorenceau J., Mango D., Mapstone M., Neri C., Nistico R., O'Bryant S. E., Palermo G., Perry G., Ritchie C., Rossi S., Saidi A., Santarnecchi E., Schneider L. S., Sporns O., Toschi N., Verdooner S. R., Villain N., Welikovitch L. A., Woodcock J., Younesi E., Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Neuroradiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Treat SVD, Laboratoire d'Imagerie Biomédicale (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), sans affiliation, Institut de la Mémoire et de la Maladie d'Alzheimer [Paris] (IM2A), Sorbonne Université (SU), Algorithms, models and methods for images and signals of the human brain (ARAMIS), Sorbonne Université (SU)-Inria de Paris, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Bordeaux (UB), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de médecine nucléaire [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre des Maladies Cognitives et Comportementales [Paris], Fraunhofer Center for Assistive Information and Communication Solutions [Porto] (Fraunhofer AICOS), Fraunhofer (Fraunhofer-Gesellschaft), Ariana Pharmaceuticals, McGill University = Université McGill [Montréal, Canada], Universidad Autonoma de Madrid (UAM), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], University of Pisa - Università di Pisa, Federal Institute of Drugs and Medical Devices [Bonn], Discipline of Psychiatry [Dublin], School of Medicine [Dublin], Trinity College Dublin-Trinity College Dublin, Universita degli Studi di Messina, University of Catania [Italy], University of Cambridge [UK] (CAM), Lou Ruvo Center for Brain Health [Las Vegas], Cleveland Clinic, Università degli Studi di Roma Tor Vergata [Roma], University of Pavia, Cardiff University, Universität Zürich [Zürich] = University of Zurich (UZH), University of California [Irvine] (UCI), University of California, Siemens Healthineers, Digital Services, Digital Technology and Innovation, In Silico Biosciences (ISB), Abdus Salam International Centre for Theoretical Physics [Trieste] (ICTP), University of California [San Francisco] (UCSF), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Manchester [Manchester], National Institute on Aging [Bethesda, USA] (NIA), National Institutes of Health [Bethesda] (NIH), Abbvie Inc. [North Chicago], Institute of Psychiatry, Psychology & Neuroscience, King's College London, King‘s College London, University of Britsh Columbia [Vancouver], Cedars-Sinai Medical Center, Functional Neuromodulation, CIBER de Enfermedades Raras (CIBERER), Institut de la Vision, Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Brain Research Institute [Rome, Italy] (EBRI), Adaptation Biologique et Vieillissement = Biological Adaptation and Ageing (B2A), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institute for Aging and Alzheimer’s Disease Research [Fort Worth] (IAADR), University of North Texas Health Science Center [Fort Worth], University of Auckland [Auckland], University of Edinburgh, Università degli Studi di Siena = University of Siena (UNISI), Harvard Medical School [Boston] (HMS), Keck School of Medicine [Los Angeles], University of Southern California (USC), Indiana State University, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital [Boston]-Harvard Medical School [Boston] (HMS), NeuroVision Imaging, Fondation pour la Recherche sur Alzheimer, Center for Drug Evaluation and Research (CDER), European Society for Translational Medicine (EUSTM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service d'Explorations Fonctionnelles Neurologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de médecine nucléaire [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Fraunhofer AICOS [Porto], McGill University, Sapienza University [Rome], University of Zürich [Zürich] (UZH), Università degli Studi di Roma 'La Sapienza' [Rome], CHU Pitié-Salpêtrière [APHP], Service de neuro-radiologie [CHU Pitié-Salpêtrière], Università degli Studi di Siena (UNISI), Harvard Medical School [Boston] (HMS)-Massachusetts General Hospital [Boston], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de la Mémoire et de la Maladie d'Alzheimer [CHU Pitié-Salpétriêre] (IM2A), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Service de Médecine nucléaire [CHU Pitié-Salpétrière], Universidad Autónoma de Madrid (UAM), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Sans affiliation, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Università degli Studi di Messina = University of Messina (UniMe), Università degli Studi di Pavia = University of Pavia (UNIPV), University of California [Irvine] (UC Irvine), University of California (UC), University of California [San Francisco] (UC San Francisco), University of British Columbia [Vancouver], Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Chiesa, P. A., Cavedo, E., Vergallo, A., Lista, S., Potier, M. -C., Habert, M. -O., Dubois, B., Thiebaut de Schotten, M., Hampel, H., Audrain, C., Auffret, A., Bakardjian, H., Baldacci, F., Batrancourt, B., Benakki, I., Benali, H., Bertin, H., Bertrand, A., Boukadida, L., Cacciamani, F., Causse, V., Cherif Touil, S., Colliot, O., Dalla Barba, G., Depaulis, M., Dos Santos, A., Dubois, M., Epelbaum, S., Fontaine, B., Francisque, H., Gagliardi, G., Genin, A., Genthon, R., Glasman, P., Gombert, F., Habert, M. O., Hewa, H., Houot, M., Jungalee, N., Kas, A., Kilani, M., La Corte, V., Le Roy, F., Lehericy, S., Letondor, C., Levy, M., Lowrey, M., Ly, J., Makiese, O., Masetti, I., Mendes, A., Metzinger, C., Michon, A., Mochel, F., Nait Arab, R., Nyasse, F., Perrin, C., Poirier, F., Poisson, C., Potier, M. C., Ratovohery, S., Revillon, M., Rojkova, K., Santos-Andrade, K., Schindler, R., Servera, M. C., Seux, L., Simon, V., Skovronsky, D., Uspenskaya, O., Vlaincu, M., Aguilar, L. F., Babiloni, C., Benda, N., Black, K. L., Bokde, A. L. W., Bonuccelli, U., Broich, K., Cacciola, F., Castrillo, J., Ceravolo, R., Corvol, J. -C., Claudio Cuello, A., Cummings, J. L., Depypere, H., Duggento, A., Durrleman, S., Escott-Price, V., Federoff, H., Teresa Ferretti, M., Fiandaca, M., Frank, R. A., Garaci, F., Geerts, H., George, N., Giorgi, F. S., Graziani, M., Haberkamp, M., Herholz, K., Karran, E., Kim, S. H., Koronyo, Y., Koronyo-Hamaoui, M., Lamari, F., Langevin, T., Lorenceau, J., Mango, D., Mapstone, M., Neri, C., Nistico, R., O'Bryant, S. E., Palermo, G., Perry, G., Ritchie, C., Rossi, S., Saidi, A., Santarnecchi, E., Schneider, L. S., Sporns, O., Toschi, N., Verdooner, S. R., Villain, N., Welikovitch, L. A., Woodcock, J., Younesi, E., and Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Apolipoprotein E, Epidemiology, Brain activity and meditation, Precuneus, Disease, Neuropsychological Tests, Hippocampus, Cohort Studies, [SCCO]Cognitive science, 0302 clinical medicine, Medicine, Longitudinal Studies, Default mode network, ComputingMilieux_MISCELLANEOUS, Brain Mapping, Subjective memory complaints, Brain functional dynamic, Health Policy, Precision medicine, fMRI, Settore BIO/14, Brain, Brain functional dynamics, Alzheimer's disease, Magnetic Resonance Imaging, Temporal Lobe, Frontal Lobe, Psychiatry and Mental health, medicine.anatomical_structure, Cohort, Biomarker (medicine), Female, Amyloid, 03 medical and health sciences, Cellular and Molecular Neuroscience, Apolipoproteins E, Developmental Neuroscience, Alzheimer Disease, Humans, Aged, Resting state fMRI, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, 030104 developmental biology, Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience, 030217 neurology & neurosurgery
Abstract: Introduction The longitudinal trajectories of functional brain dynamics and the impact of genetic risk factors in individuals at risk for Alzheimer's disease are poorly understood. Methods In a large-scale monocentric cohort of 224 amyloid stratified individuals at risk for Alzheimer's disease, default mode network (DMN) resting state functional connectivity (FC) was investigated between two serial time points across 2 years. Results Widespread DMN FC changes were shown in frontal and posterior areas, as well as in the right hippocampus. There were no cross-sectional differences, however, apolipoprotein E e4 (APOE e4) carriers demonstrated slower increase in FC in frontal lobes. There was no impact of individual brain amyloid load status. Discussion For the first time, we demonstrated that the pleiotropic biological effect of the APOE e4 allele impacts the dynamic trajectory of the DMN during aging. Dynamic functional biomarkers may become useful surrogate outcomes for the development of preclinical targeted therapeutic interventions.
Published: 2019

45. On the Importance of demand Consolidation in Mobility on Demand

Author: Giovanni Morana, Antonella Di Stefano, Andrea Di Maria, Andrea Araldo, Institut Polytechnique de Paris (IP Paris), Département Réseaux et Services de Télécommunications (RST), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), Méthodes et modèles pour les réseaux (METHODES-SAMOVAR), Services répartis, Architectures, MOdélisation, Validation, Administration des Réseaux (SAMOVAR), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP)-Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), Centre National de la Recherche Scientifique (CNRS), University of Catania [Italy], Aucta Cognitio R&D Labs, and Aucta Cognitio
Subjects: FOS: Computer and information sciences, Computer science, 0211 other engineering and technologies, Intelligent transportation systems, 02 engineering and technology, Ride-sharing, Computer Science - Networking and Internet Architecture, Transport engineering, [SPI.GCIV.IT]Engineering Sciences [physics]/Civil Engineering/Infrastructures de transport, Consolidation (business), Mode (computer interface), Range (aeronautics), 0502 economics and business, 11. Sustainability, Intelligent transportation system, Service (business), Networking and Internet Architecture (cs.NI), 050210 logistics & transportation, 021103 operations research, business.industry, Quality of service, 05 social sciences, Mobility on Demand, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, Work (electrical), ACM: I.: Computing Methodologies/I.6: SIMULATION AND MODELING, Public transport, business
Abstract: International audience; Mobility on Demand (MoD) services, like Uber and Lyft, are revolutionizing the way people move in cities around the world and are often considered a convenient alternative to public transit, since they offer higher Quality of Service (QoS-less waiting time, door-to-door service) at a cheap price. In the next decades, these advantages are expected to be further amplified by Automated MoD (AMoD), in which drivers will be replaced by automated vehicles, with a big gain in terms of cost-efficiency. MoD is usually intended as a door-to-door service. However, there has been recent interest toward consolidating, e.g., aggregating, the travel demand by limiting the number of admitted stop locations. This implies users have to walk from/to their intended origin/destination. The contribution of this paper is a systematic study the impact of consolidation on the operator cost and on user QoS. We introduce a MoD system where pickups and drop-offs can only occur in a limited subset of admitted stop locations. The density of such locations is a system parameter: the less the density, the more the user demand is consolidated. We show that, by decreasing stop density, we can increase system capacity (number of passengers we are able to serve). On the contrary, increasing it, we can improve QoS. The system is tested in AMoDSim, an open-source simulator. The code to reproduce the results presented here is available on-line. This work is a first step toward flexible mobility services that are able to autonomously re-configure themselves, favoring capacity or QoS, depending on the amount of travel demand coming from users. In other words, the services we envisage in this work shift their operational mode to any intermediate point in the range from a taxi-like door-to-door service to a bus-like service, with few served stops and more passengers on-board.
Published: 2019
Full Text: View/download PDF

46. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder

Author: Giovanni Tabbì, Michele Malaguarnera, Jean Bastin, Renata Rizzo, Richard E. Frye, Rita Barone, University of Catania [Italy], Barrow Neurological Institute, University of Arizona, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sorbonne Université (SU), Université Sorbonne Paris Cité (USPC), and École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Subjects: Autism Spectrum Disorder, [SDV]Life Sciences [q-bio], Peroxisome Proliferator-Activated Receptors, Anti-Inflammatory Agents, Peroxisome proliferator-activated receptor, Review, Resveratrol, resveratrol, Bioinformatics, Antioxidants, lcsh:Chemistry, chemistry.chemical_compound, 0302 clinical medicine, Neurodevelopmental disorder, PPARs agonists, autism spectrum disorders, mitochondrial fatty acid ß-oxidation metabolism, resveratrol, Medicine, Molecular Targeted Therapy, Receptor, lcsh:QH301-705.5, Spectroscopy, chemistry.chemical_classification, 0303 health sciences, Fatty Acids, food and beverages, General Medicine, Peroxisome, 3. Good health, Computer Science Applications, Mitochondria, Autism spectrum disorder, Oxidation-Reduction, mitochondrial fatty acid β-oxidation metabolism, Signal Transduction, autism spectrum disorders, Carbohydrate metabolism, mitochodrial fatty acid ß-oxidation metabolism, behavioral disciplines and activities, Catalysis, Inorganic Chemistry, 03 medical and health sciences, mental disorders, PPARs agonists, Animals, Humans, Physical and Theoretical Chemistry, Molecular Biology, 030304 developmental biology, business.industry, Organic Chemistry, medicine.disease, chemistry, lcsh:Biology (General), lcsh:QD1-999, business, Energy Metabolism, Flux (metabolism), 030217 neurology & neurosurgery
Abstract: International audience; Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by defective social communication and interaction and restricted, repetitive behavior with a complex, multifactorial etiology. Despite an increasing worldwide prevalence of ASD, there is currently no pharmacological cure to treat core symptoms of ASD. Clinical evidence and molecular data support the role of impaired mitochondrial fatty acid oxidation (FAO) in ASD. The recognition of defects in energy metabolism in ASD may be important for better understanding ASD and developing therapeutic intervention. The nuclear peroxisome proliferator-activated receptors (PPAR) α, δ, and γ are ligand-activated receptors with distinct physiological functions in regulating lipid and glucose metabolism, as well as inflammatory response. PPAR activation allows a coordinated up-regulation of numerous FAO enzymes, resulting in significant PPAR-driven increases in mitochondrial FAO flux. Resveratrol (RSV) is a polyphenolic compound which exhibits metabolic, antioxidant, and anti-inflammatory properties, pointing to possible applications in ASD therapeutics. In this study, we review the evidence for the existing links between ASD and impaired mitochondrial FAO and review the potential implications for regulation of mitochondrial FAO in ASD by PPAR activators, including RSV.
Published: 2019

47. EdgeMORE: Improving Resource Allocation with Multiple Options from Tenants

Author: Andrea Araldo, Antonella Di Stefano, Alessandro Di Stefano, Institut Polytechnique de Paris (IP Paris), Département Réseaux et Services de Télécommunications (RST), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), Méthodes et modèles pour les réseaux (METHODES-SAMOVAR), Services répartis, Architectures, MOdélisation, Validation, Administration des Réseaux (SAMOVAR), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP)-Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), and University of Catania [Italy]
Subjects: FOS: Computer and information sciences, Edge device, Computer science, Distributed computing, 050801 communication & media studies, Cloud computing, 02 engineering and technology, Resource Allocation, [INFO.INFO-NI]Computer Science [cs]/Networking and Internet Architecture [cs.NI], 0508 media and communications, ACM: C.: Computer Systems Organization/C.2: COMPUTER-COMMUNICATION NETWORKS/C.2.1: Network Architecture and Design/C.2.1.3: Distributed networks, Server, 0202 electrical engineering, electronic engineering, information engineering, Edge Computing, Edge computing, Cloud-Edge offloading, ACM: C.: Computer Systems Organization/C.2: COMPUTER-COMMUNICATION NETWORKS/C.2.4: Distributed Systems, business.industry, 05 social sciences, 020206 networking & telecommunications, ACM: C.: Computer Systems Organization/C.1: PROCESSOR ARCHITECTURES/C.1.4: Parallel Architectures/C.1.4.0: Distributed architectures, Service provider, Computer Science - Distributed, Parallel, and Cluster Computing, Resource allocation, Distributed, Parallel, and Cluster Computing (cs.DC), business
Abstract: International audience; Under the paradigm of Edge Computing (EC), a Network Operator (NO) deploys computational resources at the network edge and let third-party Service Providers (SPs) run on top of them, as tenants. Besides the clear advantages for SPs and final users thanks to the vicinity of computation nodes, a NO aims to allocate edge resources in order to increase its own utility, including bandwidth saving, operational cost reduction, QoE for its users, etc. However, while the number of third-party services competing for edge resources is expected to dramatically grow, the resources deployed cannot increase accordingly, due to physical limitations. Therefore, smart strategies are needed to fully exploit the potential of EC, despite its constrains. To this aim, we propose to leverage service adaptability, a dimension that has mainly been neglected so far: each service can adapt to the amount of resources that the NO has allocated to it, balancing the fraction of service computation performed at the edge and relying on remote servers, e.g., in the Cloud, for the rest. We propose EdgeMORE, a resource allocation strategy in which SPs express their capabilities to adapt to different resource constraints, by declaring the different configurations under which they are able to run, specifying the resources needed and the utility provided to the NO. The NO then chooses the most convenient option per each SP, in order to maximize the total utility. We formalize EdgeMORE as a Integer Linear Program. We show via simulation that EdgeMORE greatly improves EC utility with respect to the standard where no multiple options for running services are allowed.
Published: 2019
Full Text: View/download PDF

48. Towards metrics of sustainable food systems: a review of the resilience and vulnerability literature

Author: Thomas Allen, Paolo Prosperi, Martine Padilla, Iuri Peri, Bruce Cogill, Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM), Bioversity International [Montpellier], Bioversity International [Rome], Consultative Group on International Agricultural Research [CGIAR] (CGIAR)-Consultative Group on International Agricultural Research [CGIAR] (CGIAR), Consultative Group on International Agricultural Research [CGIAR] (CGIAR), University of Catania [Italy], and Chercheur Nord Doctorant Nord UMR Moisa
Subjects: INDICATORS, 010504 meteorology & atmospheric sciences, Vulnerability, 010501 environmental sciences, VULNERABILITE, 01 natural sciences, AGROFOOD SYSTEM, [SHS]Humanities and Social Sciences, Sustainable development, Information system, General Environmental Science, 2. Zero hunger, Food security, SECURITE ALIMENTAIRE, FOOD SECURITY, Environmental resource management, DURABILITE, Systems of information, Food and nutrition security, NUTRITION HUMAINE, SOCIAL ASPECT, Food systems, ASPECT SOCIAL, HUMAN FEEDING, INFORMATION SYSTEMS, 12. Responsible consumption, Resilience, Social–ecological systems, 2300, SUSTAINABILITY, HUMAN NUTRITION, INDICATEUR, SYSTEME D'INFORMATION, Resilience (network), Environmental planning, 0105 earth and related environmental sciences, VULNERABILITY, ALIMENTATION HUMAINE, SYSTEME AGROALIMENTAIRE, business.industry, [SDV.SA.AEP]Life Sciences [q-bio]/Agricultural sciences/Agriculture, economy and politics, ALIMENTATION DURABLE, SUSTAINABLE FOOD, 13. Climate action, Sustainability, DEVELOPPEMENT DURABLE, Socio-ecological system, Food and nutrition security Sustainable, business
Abstract: International audience; Food and nutrition security is a persisting global issue and, in addition, food systems are now facing a new set of intersecting economic, social and environmental challenges. Recurrent socio-economic and biophysical changes put the sustainability of food systems at risk. There is an urgent need to develop knowledge-based tools to assess and monitor food sustainability and to identify pathways for food security and resource conservation. The systemic nature of these interactions calls for multidimensional approaches and integrated assessments for decision-making to guide change. This paper reviews social–ecological system frameworks with the view to conceptualize the sustainability issues that affect the food systems. It is argued that the understanding of the food systems as social–ecological systems, and inputs from the theories of vulnerability and resilience in particular, can provide the concepts necessary to understand and model the complex system dynamics involved in the multiple interactions between human and natural components.
Published: 2016

49. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?

Author: Pier Luigi Meroni, Laura Damian, Cristina Belizna, Daniel Henrion, Ljudmila Stojanovich, Laurent Loufrani, Patrick Saulnier, Guillaume Mahé, Pascal Reynier, Enrique Esteve-Valverde, Jan Willem Cohen-Tervaert, Milena Hasan, Jaume Alijotas-Reig, Ferdinando Nicoletti, Alban Godon, Laurent Arnaud, Katrien Devreese, Marie Noelle Ungeheuer, György Nagy, Loukman Omarjee, Céline Fassot, Marc Antoine Pistorius, Jean Marie Chretien, Christian Muchardt, Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Belgrade [Belgrade], Maastricht University [Maastricht], Biologie Neurovasculaire Intégrée (BNVI), Semmelweis University [Budapest], Régulation épigénétique - Epigenetic regulation, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Cytometrie et Biomarqueurs – Cytometry and Biomarkers (UTechS CB), Institut Pasteur [Paris], Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources (ICAReB), CHU Strasbourg, Universitat Autònoma de Barcelona (UAB), University of Catania [Italy], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre hospitalier universitaire de Nantes (CHU Nantes), Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ghent University Hospital, MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Primary antiphospholipid syndrome, Some limitation, ERYTHEMATOSUS, Immunology, 030204 cardiovascular system & hematology, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Antiphospholipid syndrome, CARDIAC MANIFESTATIONS, Immunology and Allergy, Medicine, Humans, Lupus Erythematosus, Systemic, In patient, CLASSIFICATION CRITERIA, Secondary antiphospholipid syndrome, ANTIBODY TYPE, 030203 arthritis & rheumatology, Systemic lupus erythematosus, ANTICOAGULANT ACTIVITY, business.industry, Systemic lupus, SECONDARY, Genetic data, medicine.disease, 3. Good health, THROMBOGENIC MECHANISM, ANNEXIN A5, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, CARDIOVASCULAR-DISEASE, SYNDROME APS, Antibodies, Antiphospholipid, [SDV.IMM]Life Sciences [q-bio]/Immunology, Identification (biology), business
Abstract: International audience; Primary antiphospholipid syndrome (PAPS) and antiphospholipid syndrome associated to lupus (SAPS) have several overlapping characteristics. As systemic manifestations are also reported in patients with PAPS, and as a subgroup of PAPS patients could evaluate to a SAPS, the differentiation between the two types of APS could be performed based on the clinical experience of the medical teams and is related to a variety of clinical, biological, histological and genetic features. Several data are available in the literature with respect to the identification of distinctive features between these two entities. However, there are some limitation in the interpretation of results issued from studies performed prior to updated Sydney criteria. Based on recent data, a certain number of features more frequent in one type of APS as compared to the other could be distinguished. The major differentiation between these two entities is genetical. New genetic data allowing the identification of specific subgroups of APS are ongoing.
Published: 2018

50. Gaia GraL: Gaia DR2 Gravitational Lens Systems. III. A systematic blind search for new lensed systems

Author: Ludovic Delchambre, J. Klüter, O. Wertz, Alberto Krone-Martins, Ramachrisna Teixeira, S. G. Djorgovski, C. Ducourant, Joachim Wambsganss, Matthew J. Graham, Eric Slezak, Jean Surdej, Ulrich Bastian, Francois Mignard, Laurent Galluccio, J. F. Le Campion, D. Stern, M2A 2019, Laboratoire d'Astrophysique de Bordeaux [Pessac] (LAB), Université de Bordeaux (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Bordeaux (UB)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), University of Catania [Italy], Joseph Louis LAGRANGE (LAGRANGE), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS), Instituto de Astronomia, Geofísica e Ciências Atmosféricas [São Paulo] (IAG), Universidade de São Paulo (USP), Zentrum für astronomie, Universität Heidelberg [Heidelberg], Institut d'Astrophysique et de Géophysique [Liège], Université de Liège, Max-Planck-Institut für Astronomie (MPIA), Max-Planck-Gesellschaft, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, and Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Cosmology and Nongalactic Astrophysics (astro-ph.CO), FOS: Physical sciences, Image processing, Astrophysics, 01 natural sciences, law.invention, law, 0103 physical sciences, 010306 general physics, Instrumentation and Methods for Astrophysics (astro-ph.IM), 010303 astronomy & astrophysics, Physics, business.industry, Supervised learning, Astronomy and Astrophysics, Pattern recognition, Ellipsoid, Astrophysics - Astrophysics of Galaxies, [SDU.ASTR.IM]Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM], 3. Good health, Lens (optics), Stars, Identification (information), Gravitational lens, Discriminant, Space and Planetary Science, Astrophysics of Galaxies (astro-ph.GA), Artificial intelligence, business, Astrophysics - Instrumentation and Methods for Astrophysics, Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract: Aims: In this work, we aim to provide a reliable list of gravitational lens (GL) candidates based on a search performed over the entire Gaia Data Release 2 (Gaia DR2). We also show that the sole astrometric and photometric informations coming from the Gaia satellite yield sufficient insights for supervised learning methods to automatically identify GL candidates with an efficiency that is comparable to methods based on image processing. Methods: We simulated 106,623,188 lens systems composed of more than two images, based on a regular grid of parameters characterizing a non-singular isothermal ellipsoid lens model in the presence of an external shear. These simulations are used as an input for training and testing our supervised learning models consisting of Extremely Randomized Trees. The latter are finally used to assign to each of the 2,129,659 clusters of celestial objects a discriminant value that reflects the ability of our simulations to match the observed relative positions and fluxes from each cluster. Once complemented with additional constraints, these discriminant values allowed us to identify GL candidates out of the list of clusters. Results: We report the discovery of 15 new quadruply-imaged lens candidates with angular separations less than 6" and assess the performance of our approach by recovering 12 out of the 13 known quadruply-imaged systems with all their components detected in Gaia DR2 with a misclassification rate of fortuitous clusters of stars as lens systems that is below one percent. Similarly, the identification capability of our method regarding quadruply-imaged systems where three images are detected in Gaia DR2 is assessed by recovering 10 out of the 13 known quadruply-imaged systems having one of their constituting images discarded. The associated misclassification rate varying then between 5.8% and 20%, depending on the image we decided to remove., 12 pages, 5 figures, 4 tables, accepted in A&A
Published: 2018

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

67 results on '"University of Catania [Italy]"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources